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Abstract 
 
 
The ADAMs (A Disintegrin And Metalloproteinase) is a family of trans-
membrane and secreted proteins essential in cellular fate determination, 
wound healing, cell migration, proliferation and angiogenesis. Previous 
studies have linked a range of ADAMs, which include ADAM10 to cancer 
development and progression. Research in our laboratory found endogenous 
ADAM10 levels to be higher in both oesophageal and cervical cancer cell 
lines. Reports in the literature have highlighted a correlation between high 
levels of ADAM10 expression with that of cancer cell biology; hence ADAM10 
shows promise as an anti-cancer target.  
 
The aim of this study was to modulate ADAM10 activity in oesophageal and 
cervical cancer cell lines using the small molecule inhibitor GI254023X as well 
as previously undescribed two molecules generated en route to synthesizing 
GI254023X, namely SN-254 and SN-311. A CX3CL1 ELISA functional assay 
as an indicator of ADAM10 activity showed a decrease in CX3CL1 cleavage 
after treatment with GI254023X, SN-311 and SN-254 suggesting that all three 
compounds substantially inhibited ADAM10 activity. The effects of these 
compounds on the cell biology of WHCO5 oesophageal and HeLa cervical 
cancer cells were monitored. Our data shows that GI254023X, SN-254 and 
SN-311 inhibit oesophageal and cervical cancer cell proliferation, and cause 
		 xv	
cell death via apoptosis as observed by PARP cleavage, and elevated 
Caspase 3/7 activity. Drug treatment also resulted in an increase in cellular 
adhesion as well as a significant decrease in the invasion and migration of 
WHC05 and HeLa cells. The effect of ADAM10 inhibition on typical markers of 
the epithelial to mesenchymal transition state was also examined. An increase 
in epithelial cell markers (E-Cadherin, B-Catenin) and a decrease in 
mesenchymal marker expression (Vimentin) post treatment with the 
compounds tested strongly suggested that ADAM10 plays a role in 
mesenchymal cell transition. These results suggest that ADAM10 activity is 
necessary for the biological phenotypes that associate with cervical and 
oesophageal cancer cells and that targeting ADAM10 with inhibitors have 
potential as anticancer therapies.  
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Chapter 1: 
Introduction 
 
 
 
1.1 Preamble 
The ADAMs (A Disintegrin And Metalloproteinase) is a family of 
transmembrane bound and secreted proteins of approximately 750 amino 
acids in length, with documented functions in cell adhesion and ectodomain 
shedding of a variety of cell surface receptors and signaling molecules (Duffy 
et al., 2009). The ADAM proteins are essential in cellular fate determination, 
wound healing, cell migration, proliferation and angiogenesis (Fu, et al., 2014; 
Edwards, et al., 2008; Rocks, et al., 2008).  
 
Previous work conducted in our laboratory aimed at identifying differentially 
expressed genes that associate with cancer development using microarray 
analysis, identified ADAM10, a membrane metalloproteinase as having 
elevated expression in cervical cancer cells (Van der Watt, et al., 2009). 
Determining the endogenous expression levels of ADAM10 in oesophageal 
and cervical cancer, found an up-regulation of expression in both 
oesophageal and cervical cancer cells (Williams MSc dissertation, 2013). 
ADAM10 has thus become a protein of interest with potential to serve as a 
potential cancer biomarker. Evidence in the literature has highlighted a 
correlation between high levels of ADAM10 expression with many markers of 
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of cancer cell biology; hence, the inhibition of ADAM10 has appeal as a 
potential chemotherapeutic target (Duffy, et al., 2011; Edwards, 2008).  
 
The inhibition of ADAM10 using short hairpin RNA plasmid (shRNA) and a 
small interference RNA (siRNA) has significant effects on cancer cell biology 
including changes in cell morphology and actin organization when ADAM10 is 
inhibited (Williams, MSc Dissertation, 2013). Furthermore, the inhibition of 
ADAM10 had caused a significant increase in cell adhesion accompanied by 
decreased migration and invasion. The changes in actin organisation, cell 
adhesion, motility and invasion because of ADAM10 inhibition were properties 
all indicative of Mesenchymal-epithelial transition. In this study we aimed to 
investigate the potential of ADAM10 as a cancer biomarker and inhibit its 
activity using a known small molecule inhibitor GI254023X and two previously 
undescribed molecules. Modulating ADAM10, expression and activity will be 
monitored in two cancer types prevalent in Southern Africa, oesophageal and 
cervical cancer. 
 
1.2  Global burden of cancer 
The earliest recorded description of cancer was chronicled in the Edwin Smith 
Papyrus, written approximately 3000BC (Hadju, 2011).  Despite the multitude 
of documented texts accumulated over the millennia, our vast and ever 
growing knowledge of this disease has not yet led to its’ complete eradication 
(Hadju, 2011).  The global burden of cancer includes 14.1 million newly 
diagnosed cases per year; of which a greater proportion of these reported 
diagnoses (approximately 56%) occur within the economically developing 
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world including sub-Saharan Africa (Ferlay, et al., 2015; Varmus and Kumar, 
2013).  
Highlighting the urgency to alleviate the adverse effects of this non-
communicable disease (NCD), in 2012, a group of leading cancer researchers 
and policy makers from fifteen economically diverse countries described 
cancer as a group of diseases poised as a major liability to human life 
(Varmus and Kumar, 2013). This multi-national gathering discussed 
opportunities for global targets to reduce incidence and mortality of cancer, 
strategies to improve cancer health care, as well as to increase and develop a 
comprehensive understanding of the disease pathophysiology.  
 
A report discussing the incidence and mortality worldwide of cancer presented 
in a GLOBOCAN 2012 document, noted that approximately 8.2 million cases 
of cancer-related deaths occurred, which constitutes 13% of all reported 
deaths worldwide. Furthermore, 64% of the approximate 8.2 million cases 
were recorded within the economically developing world (Ferlay, et al., 2015; 
Jemal, et al., 2011; Ferlay, et al., 2010). GLOBOCAN 2012 further predicts 
that cancer-associated deaths globally, are projected to increase to account 
for 51% of all recorded deaths (up from 13%) within the time period of 2008 to 
2030 (± 11.5 million deaths) (Ferlay, et al., 2010).  
 
As a vast majority of recorded cancer-related deaths are reported to occur 
within the developing world, it poses a major public health risk, which is 
further aggravated by poor health care access resulting in late stage 
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diagnosis and limited access to sufficient treatment (Jemal, et al., 2011).  A 
further challenge facing economically developing nations is the reality that 
many new cancer therapies are largely inaccessible due to high costs 
incurred in drug development (Hanahan, 2014). Therefore, research into 
innovative and cost efficient diagnostic tools and therapeutic strategies 
continue.  
 
1.3 Cervical and oesophageal cancer  
1.3.1 Cancer of the cervix uteri 
An estimated 528 000 new cases of cervical cancer is diagnosed globally per 
annum, with a mortality of 266 000 in 2012 (GLOBOCAN, 2012). According to 
Arbyn and colleagues (2011), Africa has been classified as the region with the 
highest burden of cervical cancer; with 80 000 women diagnosed per annum, 
and 60 000 dying, in a population of 270 million women (aged 15 years and 
older). An estimated 7 735 women are diagnosed with cervical cancer every 
year in South Africa, representing 19.3% of all cancers in women (Bruni, et 
al., 2014; GLOBOCAN, 2012; Tathiah, et al., 2013; Vaccarella, et al., 2013). 
Furthermore, the WHO identified the Southern Africa region to have recorded 
the third highest incidence (31.5 per 100 000) and mortality rate (17.9 per 100 
000) for cervical cancer worldwide (See figure 1.1; published by: Torre, et al., 
2015). 
 
Most cervical cancer cases (>90%) are caused by the Human Papilloma Virus 
(HPV) (WHO, 2012). Of the identified 150 different HPV categories, an 
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Figure 1.1: Incidence and mortality rate of cervical cancer worldwide, 
WHO. This data spread depicts the incidence and mortality rates of cervical 
cancer in women worldwide. The graph shows Eastern Africa, Melanesia and 
Southern Africa demonstrating the highest mortality and incidence rates 
(Torre, et al., 2015).   
preventing and treating parasitic liver fluke infections.
Crop substitution and improved grain storage practices
have been used to reduce contamination with aflatoxin in
areas such as sub-Saharan Africa. Mass drug administration
for liver fluke infection and public health campaigns may
contribute to the prevention of cholangiocarcinoma.89,90
Cervical cancer
There were an estimated 527,600 new cervical cancer cases
and 265,700 deaths worldwide in 2012 (Fig. 2). It is the
second most commonly diagnosed cancer and third leading
cause of cancer death among females in less developed
countries. Incidence rates are highest in sub-Saharan
Africa, Latin America and the Caribbean, and Melanesia
and lowest in Western Asia, Australia/New Zealand, and
Northern America (Fig. 11). Nearly 90% of cervical cancer
deaths occurred in developing parts of the world: 60,100
deaths in Africa, 28,600 in Latin America and the Carib-
bean, and 144,400 in Asia. India, the second most populous
country in the world, accounted for 25% of cervical cancer
deaths (67,500 deaths). In Eastern, Middle, and Southern
Africa, as well as Melanesia, cervical cancer is the leading
cause of cancer death in females. The large geographic vari-
ation in cervical cancer rates reflects differences in the avail-
ability of screening, which allows for the detection and
FIGURE 10. Percentage of One-Year-Olds Given the Three-Series Hepatitis B Vaccination*, 2012.
*Countries with no data may represent countries where hepatitis B is not endemic (e.g., Scandinavian countries) and national hepatitis B vaccination programs
have not been introduced.
Source: World Health Organization. Global Health Observatory Data Repository, Hepatitis B (HepB3) Immunization Coverage of 1-year-olds, Data by
Country, 1985-2013 [online database]. Available from: apps.who.int/ghodata/. Accessed November 14, 2014.
FIGURE 11. Cervical Cancer Incidence and Mortality Rates by World
Area.
CA CANCER J CLIN 2015;65:87–108
VOLUME 65 _ NUMBER 2 _ MARCH/APRIL 2015 99
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estimated 40 have been identified as causative agents of infections around 
the ano-genital tract, resulting in genital warts, and pre-invasive and invasive 
lesions (Denny, 2009). Obstinate infection caused by the high-risk types 
(HPV-16, HPV-18) have been associated with 70% of cervical cancers 
worldwide, and types (HPV-6, HPV-11) are linked to 90% of genital warts 
(Denny, 2009; WHO, 2012). Currently, there exists two vaccines, Gardasil 
(Merck and Company, Whitehouse Station, NJ) and Cervarix 
(GlaxoSmithKline, Brentford, UK) available to the public (Torre, et al., 2015). 
A major barrier experienced within the economically developing world is 
access to these vaccines due to their high costs (Torre, et al., 2015). 
Overcoming this challenge, GAVI, world renowned Vaccine Alliance, 
negotiated lower prices to facilitate access and role-out of these HPV 
vaccines in economically developing countries (GAVI, 2013; Torre, et al., 
2015). 
 
Papanicolaou (Pap) smears are routinely used to assess cytological 
abnormalities from cervical swabs. This histological based Pap test, while 
proven to be highly effective in reducing the incidence and mortality of the 
disease, detects morphological changes and thus often has a high rate of 
false positive and false negative results due to inadequate specificity or 
sensitivity of the test (Nanda, et al., 2000). Liao and colleagues (1994) have 
highlighted a need for the identification of diagnostic biomarkers to 
supplement cytological tests to help address some of these problems. 
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1.3.2 Cancer of the oesophagus 
Described as the 8th most common cancer worldwide, 455 800 new cases of 
oesophageal cancer was diagnosed in 2012, with an estimated 400 200 
cancer-related deaths, rendering it the sixth most common cause of death 
from cancer within that year under review (Arnold, et al., 2015; Torre, et al., 
2015). An estimated 80% of cases reported worldwide originated from low to 
middle income regions (Arnold, et al., 2015; Ferlay et al., 2015). Oesophageal 
cancer has an incidence rate in 2012 threefold greater in males than females 
(Torre, et al., 2015). This form of cancer is known to have a very poor survival 
rate (M:I ratio is 0.88) (Arnold, et al., 2015; Ferlay, et al., 2015). The mortality 
rate within the Southern African region amongst men was 12.8 per 100,000, 
whilst in women the rate was 6.2 per 100,000 (Ferlay, et al., 2015). 
 
Malignant tumours of the oesophagus can be classified into two main 
histological subtypes, namely (i) adenocarcinoma (ADC), which developes 
from cells in the oesophago-gastric junction region or columnar epithelial cells 
in the lower oesophagus, and (ii) oesophageal squamous cell carcinoma 
(OSCC), which originates from within the stratified squamous epithelial layer 
in the upper two thirds of the oesophagus (Gatenby and Preston, 2014). 
 
Major risk factors contributing to the development of oesophageal 
adenocarcinoma include Barrett’s oesophagus and chronic gastro-
oesophageal reflux, with notable documented associations with hiatus hernia, 
obesity and smoking (Gatenby and Preston, 2014).  
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Despite steadfast advances made in diagnostic and treatment regiments for 
oesophageal cancer globally, it remains the eighth most common cancer 
worldwide (Arnold, et al., 2015; Ferlay, et al., 2013). This ever-growing global 
burden poses an even greater, more devastating effect on the health and 
economic systems of less developed regions, because approximately 80% of 
all cases reported occur within these territories (Arnold, et al., 2015; Ferlay, et 
al., 2013).  
 
In South Africa, studies have shown oesophageal cancer to be the third most 
commonly diagnosed cancer amongst the male population, with a high 
mortality rate (<10% survival rate within 3 months of diagnosis) due to the late 
diagnosis of the disease (Mqoqi, et al., 2004; Somdyala, et al., 2010). 
Furthermore, the WHO identified Southern Africa as the region with the 
second highest incidence of oesophageal cancer in males in the world (See 
figure 2.1; published by: Torre, et al., 2015). Patients with oesophageal 
cancer frequently develop resistance to currently used chemotherapeutic 
regime, underscoring the need to develop more effective and efficient tools to 
diagnose and treat this form of cancer, at an early stage.  
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Figure 1.2: Incidence rate of oesophageal cancer worldwide, WHO. This 
data spread depicts the incidence rates of oesophageal cancer in men and 
women worldwide. The graph shows Eastern Asia, Southern Africa and 
Eastern Africa, with the highest incidence rates of oesophageal cancer (Torre, 
et al., 2015).   
removal of precancerous lesions, and human papillomavirus
(HPV) infection prevalence.91-93 HPV infection prevalence
(all types) varies widely, from as high as 21% in Africa and
16% in Latin America and the Caribbean to 9% in Asia
and 5% in Northern America.92
In several Western countries, where screening programs
have long been established, cervical cancer rates have
decreased by as much as 65% over the past 40 years. For
example, in Norway, cervical cancer incidence rates
decreased from 18.7 per 100,000 in 1970 to 9.6 per
100,000 in 2011.94 Rates have also decreased in some high-
incidence areas, including Colombia, the Philippines, and
India, likely due to increased awareness and improved soci-
oeconomic conditions.93 In contrast to favorable overall
trends, cervical cancer rates are reported to be rising in
Uganda and in some countries of Eastern Europe (Estonia,
Lithuania, and Bulgaria).93 Most affected are younger
women in several countries, including many in Europe,
Central Asia, Japan, and China91,95; this cohort-driven
trend is thought to reflect increases in high-risk HPV prev-
alence from changing sexual behaviors.93
There are 2 vaccines (Gardasil [Merck and Company,
Whitehouse Station, NJ] and Cervarix [GlaxoSmithKline,
Brentford, UK]) available for protection against the 2 types
of HPV that cause most (70%) cervical cancers. In economi-
cally less developed countries, the major barrier to widespread
use is the high cost of the vaccine; however, GAVI, the Vac-
cine Alliance, has negotiated lower prices for these countries
and began rolling out HPV vaccination demonstration
projects in supported countries in 2013.96 It is extremely
important that all women, even those who have been vacci-
nated, continue to be screened, because HPV vaccines cannot
protect against established infections, nor do they protect
against all of the types of HPV that cause cervical cancer.
Many low-resource countries do not have the technical
and public health infrastructure to support Papanicolaou
testing, the most common screening tool for cervical cancer
in more developed countries. The most efficient and cost-
effective screening techniques in low-resource countries
include visual inspection using acetic acid and HPV tests.97
A clinical trial in rural India found that a single round of
HPV testing reduced the number of cervical cancer deaths
by about 50%.98
Esophageal cancer
An estimated 455,800 new esophageal cancer cases and
400,200 deaths occurred in 2012 worldwide (Fig. 2).
Esophageal cancer incidence rates vary internationally by
more than 21-fold. The highest rates are found in Eastern
Asia and in Eastern and Southern Africa and the lowest
rates are found in Western Africa (Fig. 12). Esophageal
cancer is usually 3 to 4 times more common among men
than women. The 2 main types of esophageal cancer are
squamous cell carcinoma and adenocarcinoma. In the
highest-risk area, often referred to as the “esophageal can-
cer belt,” which stretches from Northern Iran through the
Central Asian republics to North-Central China, 90% of
cases are squamous cell carcinomas, compared with about
26% in the United States (among white individu-
als).83,99,100 In high-risk areas such as Golestan (Iran) and
Linxan (China), contributing risk factors are not well
understood, but are thought to include poor nutritional sta-
tus, low intake of fruits and vegetables, and drinking bever-
ages at high temperatures.101-104 HPV infection has been
detected in squamous cell carcinomas, particularly in high-
risk areas in Asia. However, more research is needed to
determine whether HPV or other infectious agents increase
risk.105-108 The primary risk factors for squamous cell carci-
noma in Western countries are alcohol and tobacco use,
which account for almost 90% of total cases.
The main known risk factors for esophageal adenocarci-
noma are overweight and obesity and chronic gastroesopha-
geal reflux disease (GERD). GERD can cause metaplastic
changes to the esophagus, referred to as Barrett esophagus,
that predispose to dysplasia and adenocarcinoma. However,
only a small percentage of those with Barrett esophagus go
on to develop esophageal cancer.109 GERD is most com-
mon in overweight men and women. Smoking and low
intake of fruits and vegetables are also risk factors for ade-
nocarcinoma of the esophagus.
Temporal trends in esophageal cancer vary greatly. For
example, although incidence rates of esophageal squamous
cell carcinoma have been increasing in some Asian countries,
FIGURE 12. Esophageal Cancer Incidence Rates by Sex and World Area.
Global Cancer Statistics, 2012
100 CA: A Cancer Journal for Clinicians
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1.4 Hallmarks of cancer 
Cancer is a multifaceted disease and in 2000, Hanahan and Weinberg initially 
described six hallmarks of cancer. In 2011, Hanahan and Weinberg proposed 
the addition of two emerging hallmarks of cancer, namely: “deregulating 
cellular genetics,” and, “avoiding immune destruction”. Two important 
enabling characteristics of neoplastic acquisition were identified; genomic 
instability and mutation, as well as tumour promoting inflammation (Hanahan 
and Weinberg, 2011; Cavallo, et al., 2011). Figure 1.3 below, graphically 
displays the Hallmarks of Cancer. 
 
Figure 1.3: The Hallmarks of Cancer. (Hanahan and Weinberg, 2011).  
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The role played by the Hallmarks relevant to this study are reviewed below: 
i. Growth factor independence or self-sufficiency of growth factors: 
The binding of a ligand to a specific receptor leads to the eventual transfer of 
a signal from the membrane towards the nucleus via a cascade of multiple 
intermediary messengers in the case of membrane-bound receptors 
(Harrington, 2016). Under normal cellular conditions, the synthesis and 
activation of ligands responsible for growth factor receptor activation is tightly 
monitored and regulated; however, cancer cells are able to achieve self-
sufficiency of growth signal by ubiquitously deregulating this signaling 
pathway, thereby using these signals to drive unrestrained cellular division 
(Harrington, 2016; Rogers, et al., 2005; Hanahan and Weinberg, 2011; 
Cavallo. et al., 2011). 
ii. Insensitivity to anti-growth signals: 
Anti-growth signals counteract the growth signals by either forcing cells into a 
quiescent state (G0 phase of the cell cycle) or by initiating a terminal 
differentiation state of the cell thereby ensuring a permanent inability of the 
cell to re-enter the cell cycle. Abnormalities in these signaling pathways are 
commonplace in cancer thus ensuring progress of the cancer cells through 
the cell cycle (Hanahan and Weinberg, 2011; Harrington, 2016). 
iii. Avoidance of cell death: 
Within normal cells, if DNA damage occurs during replication (endogenous 
DNA damage) or due to a genotoxic event (exogenous DNA damage), cell 
cycle arrest would take place whilst the repair of DNA is executed (Hanahan 
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and Weinberg, 2011; Harrington, 2016). If the damage to DNA exceeds the 
capacity for repair, the cell undergoes a form of programmed cell death 
(apoptosis or autophagy) (Harington, 2016). Tumorigenesis involves the loss 
of normal regulated cell death signaling pathways, thereby evading 
programmed cell death. By circumventing apoptosis or autophagy, cancer 
cells are able to survive and proliferate despite DNA damage, consequently 
passing the damaged DNA on to the daughter cells (Adam and Cory, 2007; 
Hanahan and Weinberg, 2011; Harrington, 2016).      
iv. Sustained angiogenesis: 
Growth of new blood vessels (angiogenesis) is regulated tightly by pro-
angiogenic and anti-angiogenic cellular signals (Harrington, 2016). The ability 
of pre-neoplastic cells to develop into full-blown cancer cells is related to its’ 
capability to attract and secure a new blood supply. Tumorigenesis involves 
activating an “angiogenic phenotype” by means of increasing and up-
regulating the production of pro-angiogenic factors e.g. vascular endothelial 
growth factor (VEGF), whilst simultaneously down-regulating the production 
and release of anti-angiogenic proteins such as angiostatin (Hanahan and 
Weinberg, 2011; Harrington, 2016).  
v. Invasion and metastasis: 
The invasion-metastasis cascade comprising of discrete sequential steps 
includes the detachment of tumorigenic cells from within the immediate 
surrounding microenvironment, coupled with an enzymatic-driven degradation 
of the extracellular matrix (ECM) allowing for mobility of cells (Harrington, 
2016). Following motility of cancer cells, intra-vasation of blood or lymphatic 
	 13 
vessels occur, causing tumour to embolize (Hanahan and Weinberg, 2011; 
Harrington, 2016). Survival of the tumour emboli is essential until a favourable 
colonization site is located. Once such a site is identified, attachment of the 
emboli and subsequent extravasation through the vessel wall takes place. 
The successful proliferation and ensuing invasion of the new locality is 
achieved through inducing angiogenesis. (Alizadeh, Shiri and Farsinejad, 
2014; Hanahan and Weinberg, 2011). 
 
Some of the key processes explored in this project relate to altered cell 
morphology, motility and invasion, key elements of metastasis. These are also 
key elements of another important cellular process termed epithelial to 
mesenchymal transition (EMT).   
 
1.5 Epithelial to Mesenchymal Transition (EMT) 
Epithelial to mesenchymal transition (EMT) is that process where polarized 
epithelial cells undergo a host of changes (morphology, cellular architecture, 
adhesive properties and migratory capacity) resulting in detachment and 
release of highly motile, fibroblast-like mesenchymal cells (Kalluri and 
Weinberg, 2009). This transitional process is regulated by gene expression 
changes and subsequent degradation of adherens junctions, causing an 
increased ability of cells to migrate and subsequently invade surrounding 
tissue (Figure 1.4) (Kalluri and Weinberg, 2009; Lee and Nelson, 2012; 
Thiery, 2002; Thiery, et al., 2009).  
 
	 14 
 
 
Figure 1.4 Morphologic, phenotypic, and molecular marker differences 
between epithelial cells and highly invasive mesenchymal cells. 
Epithelial cells posses a highly polarized morphology with distinct apical and 
baso-lateral plasma membrane domains. During the process of EMT, well-
differentiated epithelial cells acquire an invasive mesenchymal morphology. 
Mesenchymal cells do not form extensive intercellular junctions. These cells 
possess different cytoskeletal arrangements and express a different profile of 
genes, relative to epithelial cells (Figure adopted from: Christiansen, and 
Rajasekaran, 2006). 
 
Physiologically, EMT plays important roles during embryonic development 
and wound healing. Loss of proper control over EMT can lead to fibrosis, 
organ dysfunction, tissue dysfunction and in the case of cancer, metastasis. 
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This often reversible transition process in cell phenotype has been classified 
into three types, namely: Type I – Embryogenesis and organ development, 
Type II – Fibrosis (wound healing and tissue regeneration); and Type III – 
Metastasis (Klymowsky and Savagner, 2009; Shook and Keller, 2003; 
Cervantes-Arias, et al., 2013). 
 
The induction of Type-III EMT involves both extrinsic and intrinsic stimuli 
where the surrounding microenvironment of tumour cells acts as an extrinsic 
stimulus in facilitating further cancer development and metastasis (Cervantes-
Arias et al., 2013).  
 
A critical step in the progression of EMT activation involves the reduction of E-
cadherin expression on epithelial cells (Thiery, 2003; Acloque, et al., 2009; 
Cervantes-Arias, et al., 2013). The Snail family of proteins (an E-Cadherin 
repressing family) are known EMT inducing factors, which promote the 
interaction of the tumour cell with its microenvironment  (Voulgari and Pintzas, 
2009; Moustakas and Heldin, 2005).  
 
Coupled to its central role in cell adhesion, E-Cadherin is known for its cell 
signaling activity with a range of regulatory proteins, such as β-Catenin, a 
stabilizing factor within adherens junctions located between adjacent cells 
(Thiery, 2003; Acloque, et al., 2009). Wnt pathway signaling has been 
reported to result in β-Catenin release from E-Cadherin and translocation to 
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the nucleus where β-Catenin has been shown to increase the levels of 
numerous transcriptional factors of EMT-related proteins, which include Twist, 
Slug and Snail (Cervantes-Arias, et al., 2013).  
 
1.6 The ADAMs family 
1.6.1 Background 
The ADAMs (A Disintegrin And Metalloproteinase) is a family of proteins 
present in invertebrate species and all vertebrates (Edwards, et al., 2008). 
ADAMs are implicated in the control of multiple cellular and developmental 
activities that include cytokine and growth factor shedding, membrane fusion, 
cellular migratory as well as invasive properties (Seals and Courtneidge, 
2003; Fu, et al., 2014; Edwards, et al., 2008; Rocks, et al., 2008). Extensive 
literature reviews have also highlighted the involvement of ADAMs in 
pathologies such as pro-inflammatory microenvironment development as well 
as tumourigenesis (Giebeler and Zigrino, 2016; Seals and Courtneidge, 
2003). 
 
The members of the ADAM family were first identified in guinea pig sperm 
studies. These studies aimed to identify membrane surface proteins targeted 
by the monoclonal antibody PH30 (Giebeler and Zigrino, 2016; Seals and 
Courtneidge, 2003; Primakoff, et al., 1987). These sperm surface proteins 
contained both metalloproteinase-like and disintegrin-like domain regions, 
structurally similar to that of the snake venom metalloproteinase protein 
(SVMP) domain (See figure 1.5) (Giebeler and Zigrino, 2016; Seals and 
Courtneidge, 2003; Wolfsberg, et al., 1995). The identification of these two 
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domains, led to their combination, in name, giving rise to the term ADAM, as it 
contained both ‘A Disintegrin’ and ‘A Metalloproteinase’ domain within its 
structure (Giebeler and Zigrino, 2016; Wolfsberg, et al., 1995). Belonging to 
the metzincin superfamily of proteases, ADAMs, also known as MDC proteins 
(metalloproteinase / disintegrin / cysteine-rich), are zinc-dependent 
proteinases (Giebeler and Zigrino, 2016).  
 
 
Figure 1.5: A topographic representation of the ADAMs and related 
metalloproteinases. Generalized domain structures of the ADAMs, SVMPs, 
and ADAM-TS, families are shown above. Note that ADAM-TS family 
members have a variable number of thrombospondin-like (TS) motifs 
(Giebeler and Zigrino, 2016).  
 
 
1.6.2 Structural overview 
The ADAMs is a family of type 1 transmembrane bound and secreted proteins 
of approximately 750 amino acids in length, with documented functions in cell 
adhesion and ectodomain shedding of a variety of cell surface receptors and 
Pro = Prodomain 
MP = Metalloproteinase 
D = Disintegrin (-like) 
C = Cysteine-rich 
E = EGF-like 
TM = Transmembrane 
CT = Cytoplasmic 
S = Spacer 
xTS = Thrombospondin repeats 
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Together with snake venom metalloproteases (SVMPs), ADAM and ADAMTS (a disintegrin
and metalloproteinases with thrombospondin motif) proteins form the M12 (MEROP database;
https://merops.sanger.ac.uk/) Adamalysin subfamily of metallopeptidases. ADAMs have been
detected in various species, from Ciona intestinalis to mice and humans [1]. Phylogenetic and molecular
evolutions studies on these proteins have identified several g ne duplications followed by pseudogene
formation and/or positive selection of those genes mostly related to reproduction thus ensuring
survival of the species [2]. Duplications and speciation have probably contributed to the divergence
of SVMP and ADAM from the common ancestor gene [3]. Similarities in domain organization
and sequences exist between the ADAMs and the P-III SVMPs [4]. Both protein families contain
a pro-domain, a metalloproteinase and a disintegrin domain, and a cysteine domain. The latter
in ADAMs has cell adhesive and fusogenic potential. ADAMs also contain an EGF-like repeat, a
transmembrane domain, and a cytoplasmic tail (Figure 2). In addition, the tails of some ADAMs
have intrinsic signaling activity and regulate proteolysis [5]. Alternative splicing of ADAMs produces
proteins with different localization and activity [6].
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Figure 2. General structure of ADAMs (a disintegrin and metalloproteinases), ADAMTSs (a disintegrin
and metalloproteinases with thrombospondin motif), and SVMPs (snake venom metalloproteases).
The label “disintegrin” was initially given to describe snake venom cysteine-rich, RGD-containing
proteins able to adhere to integrins and inhibit platelet aggregation and cause hemorrhage in snake
bite victims [7]. Similar to SVMPs, ADAMs adhere to integrins even though their binding sequence
mostly contains an aspartic acid-containing sequence ECD (or xCD sequence) instead of the typical
RGD amino acid sequence, except for human ADAM-15 (Figure 3). For this reason these domains
are referred to as “disintegrin-like” domains [8]. Structural analysis of resolved structures of the
ADAM and SVMP domains has been extensively reviewe elsewhere [9,10]. Only half of the
known ADAMs contain a catalytic-Zn binding signature for metalloproteases (HExGHxxGxxHD)
in their metalloprotease domain and can potentially be catalytically active. Those mammalian
ADAMs that are catalytic lly active use a cysteine-switch mechanism to maintain enzyme latency [11].
Interestingly, the pro-domain not only is implicated in this process, but is also important for the correct
protein folding and intracellular transport through the secretory pathway as shown for example for
ADAM-9, -12, and -17 [12–14].
	 18 
signaling molecules (Duffy, et al., 2009). The ADAMs are essential in cellular 
fate determination, wound healing, cell migration, proliferation and 
angiogenesis (Fu, et al., 2014; Edwards, et al., 2008; Rocks, et al., 2008).  A 
member of the metzincin superfamily of metalloproteinases  (zinc protease 
subfamily), ADAM is structurally composed of six domains, each performing a 
specific function (Seals and Courtneidge, 2003).   
 
The structural domains of ADAM include: a prodomain region, noted for its 
ability to assist as a intra-molecular chaperone, as well for its’ ability to block 
potential protease activity (Edwards, et al., 2008; Roghani, et al., 1999); a 
metalloproteinase region (regulates protease activity, as well as guiding 
substrate specificity); a disintegrin domain (assists in cellular adhesion 
activity), an epidermal growth factor (EGF)- like domain (reported to stimulate 
and aid in membrane fusion) and a cytoplasmic-tail domain, a region rich in 
proline residues, shown to interact with Src homology 3 domain-containing 
proteins (Duffy, et al., 2009), and shown in Figure 1.6. ADAM presents as a 
pro-enzyme (enzymatically inactive precursor protein) due to a cysteine 
residue (located within the pro-domain site) interacting with a zinc ion at the 
catalytic site (Edward, et al., 2008; Duffy, et al., 2009; Duffy, et al., 2011). To 
ensure full metalloproteinase activation, the prodomain region is removed 
either by means of a furin-like convertase reaction, or via autocatalysis both 
resulting in proteolytic cleavage (Edwards, et al., 2008, Murphy, 2008; Duffy, 
et al., 2011).  
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Approximately 50% of ADAMs contain a highly conserved catalytic region, 
with a consensus sequence of – HEXGHXXGXXHD – constituting a Zinc 
binding motif within its protease domain region (Duffy, et al., 2009; 2011). The 
successful hydrolytic processing of protein substrates of ADAM require this 
zinc-binding motif consisting of three histidine residues as well as a highly 
conserved methionine region within the active site of the helix region (Reiss, 
Ludwig and Saftig, 2006).  
 
Downstream of the proteolytic domain, is the disintegrin region comprising 
~90 amino acids (Duffy, et al., 2009; 2011). The disintegrin domain is 
important for cellular adhesion activities, key in directing binding of ADAMs to 
the integrins (Duffy, et al., 2009; 2011). The cysteine rich domain located on 
the C-terminal side of the disintegrin domain regulates the catalytic activities 
of ADAM. It is the cysteine region that controls substrate targeting as well as 
the cleavage of the pro-domain region from the catalytic region of the ADAM 
structure (Duffy, et al., 2009; Duffy, et al.,2011; Reiss, Ludwig and Saftig, 
2006). The cytoplasmic C-terminal tail of ADAMs vary in sequence length. 
This particular region is known to be rich in proline residues thus it possesses 
binding site motif structures for Src homology 3 (or SH3) domain-containing 
protein, with potential sites for phosphorylation (Reiss, Ludwig and Saftig, 
2006). Functionally, this domain site is reported to be involved in the 
regulation of protease function (Duffy, et al., 2009; Duffy, et al., 2011; Reiss, 
Ludwig and Saftig, 2006).  
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Figure 1.6: Schematic diagram of ADAM. A large amino-terminal 
propeptide (PRO) (Edwards et al., 2008; Murphy, 2008); a metalloproteinase 
domain (MP) a carboxy-terminal region split into three segments, namely: a 
disintegrin domain (DIS), cysteine-rich region (CR) and an epidermal growth 
factor-like repeat (EGF).  The ADAM - DIS and CR domains are documented 
to form a disulphide bonded entity exposing a hypervariable region (HVR) in 
the CR domain. The remaining domains within ADAM are the cytoplasmic 
domain (CD) and the transmembrane domain (TM) (Murphy, 2008).  
 
1.6.3 ADAM and cancer expression levels 
Considering the wide range of biological processes that the ADAM protein are 
involved in, it is perhaps unsurprising that ADAMs have also been implicated 
in tumorigenesis (Duffy, et al., 2009). These activities include tumour necrosis 
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PRO
DISMP
EGF
TM
CRHVR
CD
Furin-like
Enzymes of the proprotein 
convertase family that largely 
reside in the endoplasmic 
reticulum and are involved in 
post-translational processing of 
hormones and other proteins. 
The substrate cleavage 
specificity is carboxy-terminal 
to either single or paired basic 
residues, with the Lys–Arg 
motif being the most common.
CAM) and selectins41, among others. Proteolysis of 
E-cadherin and the subsequent activation of B-catenin 
are features of epithelial–mesenchymal transition, 
which occurs when cell adhesions are lost and the 
process of cell migration begins. Hence, the shedding 
of E-cadherin by ADAM10 modulates the subcellular 
localization of B-catenin and downstream signalling to 
cyclin D1, enhancing cell proliferation42.
Interestingly in terms of cancer, ligands of the acti-
vating natural killer cell receptor, NKG2D, including 
the tumour-associated major histocompatibility com-
plex class 1 related proteins MICA and MICB, may be 
shed by ADAM17 (REF. 43). This loss of an immuno-
genic signal is thought to promote resistance to cancer 
by inducing internalization and degradation of NKG2D 
and stimulation of populations of T cells with negative 
regulatory functions. During apoptosis, cells shed many 
of their surface proteins and it is clear that ADAMs have a 
significant role in this activity35,44. For example, ADAM10 
activity at the tumour cell surface or within shed vesicles 
is responsible for the solubilization of membrane cofac-
tor protein CD46, which controls complement activation 
on cells and modulates immune responses by affect-
ing CD8+ T cells, hence downregulating local immune 
responses44.
ERBB regulation. The Erbb family of receptor tyrosine 
kinases are important regulators of cell fate and have 
been intensely studied and targeted in breast and other 
cancers45,46. ADAM17 is a major sheddase for the EGFR 
and other Erbb receptor ligands, including the proforms 
of heparin-binding EGF-like growth factor (HBEGF), 
transforming growth factor-A (TGFA), amphiregulin 
and epiregulin32. Studies of mice in which the catalytic 
domain of ADAM17 has been ablated indicate simi-
larities to an Egfr–/– phenotype and the analysis of iso-
lated Adam17–/– embryonic fibroblasts have shown that 
ADAM17 is a major regulator of EGFR signalling32. This 
has implications for many cancers in which signalling 
from EGFR affects cell proliferation and the migra-
tion both of tumour cells and stromal cells. In addition, 
ADAM10 can release soluble EGFR ligands that also 
occur in tumours, such as B-cellulin and EGF32,47.
Recent studies have shown that increases in the 
levels of Erbb receptor ligands may abrogate the effec-
tiveness of inhibitors of their intracellular signalling; 
hence, the development of ADAM inhibitors is an area 
of preclinical activity48,49. ADAM-mediated proteo-
lysis of other Erbb receptors has also been described 
in human tumour cell lines, with implications for their 
signalling activities46,48–50. Studies of serum from cancer 
patients have also found proteolysed soluble forms of 
the Erbb receptors51. Detection of soluble ERBB2 has 
been correlated with poor prognosis for breast cancer 
patients and several studies have suggested that cleavage 
of ERBB2 activates the membrane-bound portion into 
a constitutively active kinase. Furthermore, the soluble, 
or shed, part of the molecule could neutralize thera-
peutic anti-ERBB2 antibodies. For example, Liu et al. 
found that an inhibitor of ADAM10, which was more 
effective than an ADAM17 inhibitor, inhibited ERBB2 
solubilization and potentiated the activity of low-dose 
trastuzumab (an ERBB2 antibody) in vitro50.
Biochemical studies had indicated that a number 
of the proteolytic ADAMs could act as the sheddases of 
Erbb ligands. Both loss-of-function studies and the com-
plementary gain-of-function studies in mice with spe-
cific Adam gene ablations and cells derived from them 
were used to resolve the question of which ADAMs 
may be cleaving which ligands in vivo. Distinct roles for 
ADAM10 and ADAM17 in the shedding of different 
ligands were mapped out, according to the stimulus and 
the cell type52. Gain-of-function studies showed that 
several proteolytic ADAMs have varying abilities to 
release EGFR ligands52. As many of these ADAMs appear 
to be expressed in cancers we can surmise that they could 
contribute to Erbb signalling, with consequences for cell 
proliferation, viability and many other effects45. Future 
Figure 2 | Schematic diagram of the domain structure of the Adam (a disintegrin 
and metalloproteinase) family. The Adam family of transmembrane proteins is defined 
by a distinct domain structure. A large amino-terminal propeptide (PRO) that has a role 
in initial protein folding also keeps the catalytic activity in check during intracellular 
trafficking60. Although cleav ge of the propeptide from the metalloproteinase domain by 
furin-like enzymes occurs in the Golgi or later in the secretory pathway, it seems that the 
propeptide may remain bound within the catalytic cleft (metalloproteinase domain 
(MP)), requiring displacement and acting as a further level of regulation113. Three distinct 
regions carboxy-terminal to the catalytic domain (disintegrin domain (DIS), disulphide 
bonded to a cysteine-rich region (CR) often containing an epidermal growth factor-like 
repeat (EGF)) constitute the remainder of the Adam ectodomain. From structural data for 
the closely related snake venom haemo rhagins114 and for isolated domains of ADAM10 
(REF. 115) it appears that the DIS and CR domains form a disulphide bonded entity 
exposing a hypervariable region (HVR) in the CR domain that is likely to be a major 
interaction site with other molecules, including substrates116,117. Many studies have 
shown ADAMs to have integrin-binding activity, which was attributed to the DIS domain, 
but the haemorrhagin structures show that the putative di i tegrin lo p is packed 
against a subdomain of the CR and would be inaccessible for protein binding, unless 
significant conformational changes can occur that are not represented in the crystal 
structure114. Nevertheless, integrin interactions are clearly of some importance for Adam 
biology, but are outside the scope of this article. The crystal structures indicate that the 
Adam ectodomains are C-shaped with the catalytic site and the HVR juxtaposed. 
Preliminary studies using chimaeras of different domains from different ADAMs do imply 
that these extra-catalytic regions might confer specificity to an individual ADAM and 
could form the basis for studies of more targeted inhibitors than has been achieved with 
catalytic domain interactants118. CD, cytoplasmic domain; TM, transmembrane domain.
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factor alpha (TNF-α) release, as well as the shedding of HER/ EGFR ligands 
(Duffy, et al., 2009). Epidermal growth factor receptor (EGFR) and HER2, 
members of the EGFR family, are involved in cellular survival, growth, 
migration and invasion activities, as well as pro-angiogenic activities (Duffy, et 
al., 2009). Due to their role in these cellular processes, any altered elevated 
expression level of ADAM on the surface of cells have been implicated in 
cancer progression and proliferation (Duffy, et al., 2009; Lu, et al., 2008). 
 
Described as a pluripotent peptide, TNF- α assists in activities key to tumour 
formation and progression (Duffy, et al., 2009; Lu, et al., 2008). These 
processes include its ability to up-regulate matrix metalloproteinase (MMP) 
expression levels, thereby enhancing cellular migration, promotion of 
epithelial to mesenchymal transition, induction of pro-angiogenic growth and 
development factors, as well as the release of reactive oxygen species known 
to damage DNA (Duffy, et al., 2009; Lu, et al., 2008).  
 
Overexpression of members of the ADAMs family have been reported in 
cancer of the brain, breast, colon, lungs, oesophagus, stomach and prostate. 
Overexpression of ADAM-8 has been associated with renal, lung and brain 
cancer (Mochizuki and Okada, 2007). In primary brain carcinoma, ADAM-8 
associates with an increase in invasiveness and rapid progression 
(Wildeboer, et al., 2006). The association between invasive metastatic spread 
and high levels of ADAM-8 expression in tissues has also been seen in 
patients with pancreatic cancer (Valkovskaya, et al., 2007; Lu, et al., 2008). 
These results show that ADAM-8 is associated with tumour migration and 
invasion properties. ADAM-8 has also been reported to be a potential 
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biomarker for prognosis in lung adenocarcinoma, since greatly elevated levels 
of ADAM-8 were observed in cancer patient serum samples compared to 
healthy patient controls  (Lu, et al., 2008; Mochizuki and Okada, 2007).  
 
ADAM-9 overexpression has been reported to associate with cancers of 
breast, pancreas, skin, and lung origin (Lu, et al., 2008; Mochizuki and Okada, 
2007). Elevated levels of ADAM-9 in breast cancer have been reported to 
contribute to the release of HB-EGF (O’Shea, et al., 2003). ADAM-9 
overexpression has also been reported in pancreatic ductal adenocarcinoma 
(PDAC), distinguishing it from other pancreatic tumours (Edwards, et al., 
2008; Lu, et al., 2008; Mochizuki and Okada, 2007). In lung carcinoma, 
ADAM-9 up-regulation assists in the enhancement of invasion properties of 
non-small cell lung cancer, done so by modulating, altering adhesive 
molecular properties and, in so doing, promoting metastasis (Edwards, et al., 
2008; Lu, et al., 2008; Mochizuki and Okada, 2007). 
 
Increased levels of ADAM-12 have been reported in breast tumour 
proliferation (Lu, et al., 2008; Mochizuki and Okada, 2007), as well as in 
bladder, colon and lung carcinoma development (Lu, et al., 2008; Mochizuki 
and Okada, 2007).  
 
Increased expression levels of ADAM-15 have been associated with cancer 
development and progression in the breast, prostatic, stomach and lung 
tissues respectively (Mochizuki and Okada, 2007). Known to have a role in 
metastasis, ADAM-15, aids both in the detachment of cells from the ECM via 
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its disintegrin-like domain, and by means of degrading the ECM through its 
metalloproteinase structural region (Lu, et al., 2008).  
  
ADAM-17 overexpression has been identified within cancers of breast, renal, 
ovary and prostate origin (Mochizuki and Okada, 2007). Reportedly 
responsible for the release of proteins such as tumour necrosis factor alpha 
(TNF-α) and Amyloid Precursor Protein (APP), ADAM-17 has been shown to 
be a potentially viable biomarker and target for drug therapy (Moss, et al., 
2001; Mochizuki and Okada, 2007). Sharing a ~35% identity to ADAM-10 
gene sequence, ADAM-17 has been shown to perform similar functions to 
ADAM-10 (Mochizuki and Okada, 2007). In breast carcinoma, ADAM-17 
overexpression has been reported to cause significant increases in cell 
proliferation and invasion, whilst down-regulation of ADAM-17 results in a 
decrease in invasive properties (Lu, et al., 2008; Mochizuki and Okada, 2007). 
 
ADAM-19 has been reported to be up-regulated in human primary brain 
tumours, and associate with invasive properties in glioma cells (Wildeboer, et 
al., 2006).  
 
ADAM-28, is expressed as two forms, anchored to a membrane, as well as in 
a short secreted form (Lu, et al., 2008). ADAM-28 is found to be 
overexpressed in human breast carcinoma, suggesting an involvement in both 
cellular proliferation as well as invasion and migration properties (Lu, et al., 
2008). 
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Previous work done in our laboratory using microarray analysis identified 
differentially expressed genes that associate with cervical cancer (Van der 
Watt, et al., 2009; Ward, et al., 2011). Amongst the genes identified and 
validated further, ADAM-10 was found to show significant increased 
expression in both cervical and oesophageal cancer tissue samples when 
compared to normal tissue samples.  
 
1.6.4 ADAM-10 and cancer  
 
1.6.4.1 Structural features 
Described as a membrane sheddase protein, ADAM-10 has an inactive 
(85kDa) and active mature (65kDa) protein size (Tousseyn, et al., 2009). 
Although similar in structural domain features, ADAM10 is known to possess 
both the cysteine rich and EGF-like domain, prevalent in other ADAM proteins 
(Reiss, Ludwig and Saftig, 2006). 
 
1.6.4.2 Role of ADAM-10 in cancer development and progression 
ADAM-10 has been reported to be overexpressed in cancers, including colon, 
prostate and ovarian (Arribas, et al., 2006; Zhang, et al., 2014; Zhao, et al., 
2014). ADAM-10 is involved in the intramembranous proteolytic processes of 
mediating ectodomain shedding of various membrane-bound receptors, 
growth factors, adhesion molecules and cytokines (Endres and Fahrenholz, 
2010; Mochizuki and Okada, 2007).  ADAM-10 substrates include betacellulin, 
epidermal growth factor (EGF), Notch, collagen IV, CD-44 and E-Cadherin 
(Duffy, et al., 2011; Moss, et al., 2008; Moss, et al., 2007).   There is evidence 
	 25 
in the literature that ADAM-10 substrates aid in the development and 
progression of tumours.  
 
A well-studied example of active ADAM-10 involvement in intramembraneous 
proteolytic activation is seen in the solubilisation of a range of cell adhesion 
molecules, including E-Cadherin, and the proteolytic cleavage of CX3CL1 
(Caolo, et al., 2015). Increased levels of B-Catenin freed from a complex of E-
Cadherin-B-Catenin, activates cyclin D1, thus enhancing cellular proliferation 
(Caolo, et al., 2015; Maretzky, et al., 2005); increasing epithelial to 
mesenchymal transition; enhancing cellular migration, essentially enabling 
opportunities for tissue invasion and metastasis of tumour cells (Ma, et al., 
2007). As ADAM-10 is associated with various processes linked to cancer 
development, it presents a promising target for cancer therapy. 
 
1.7 Small molecule inhibitors of ADAMS family 
 
1.7.1  Development of ADAM-10 targeted small molecule inhibitor 
The inhibition of ADAM-10 is considered a promising strategy aimed at 
targeting cellular proliferation, invasion and migration in cancer. Several 
synthesized inhibitors for ADAM-10, i.e. batimastat and marimastat, which 
belong to the peptidomimetic hydroxamic acid inhibitors for metalloproteinase, 
have been investigated (Groves, et al., 2006; Hoettecke, et al., 2010; 
Hundhausen, et al., 2003). Recent studies have demonstrated that although 
these inhibitors can affect numerous metalloproteinase, they lack in protein 
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receptor selectivity, hence contributing to their failure in clinical trials (Groves, 
et al., 2006; Hoettecke, et al., 2010).  
 
The GI254023X (see figure 1.7 of its chemical structure) compound was 
designed to fit the active cleft site (catalytic domain) of the available ADAM-17 
X-ray crystal structure (Ludwig, et al., 2005), whilst using a hydroxamate 
ligand as a peptidic backbone template. The modeling program used, showed 
the hydroxamate group binding to the catalytic zinc site, with its P1” isobutyl 
substituent (leucine-like side-chain) directed into the S1’ pocket (Ludwig, et 
al., 2005). Despite being modeled as an inhibitor against ADAM-17, 
GI254023X displays a stronger potency to ADAM-10, than ADAM-17. 
Molecular modeling analysis illustrate that amino acid differences in the active 
site between ADAM-10 and ADAM-17 contribute to enhanced hydrophobic 
interaction between GI254023X and ADAM-10, improving its potency in 
ADAM-10 (Ludwig, et al., 2005).   
 
Therefore, the molecular modelling GI254023X shows a clear distinction at 
the P1’ position within the pseudopeptidic part of the molecule, therefore 
differing from a broad- spectrum metalloproteinase inhibitors, due to a large 
hydrophobic substitution (Ludwig, et al., 2005). The lipophilic substitution 
within this P1’ position of GI254023X hydroxymate inhibitor contributes to the 
compounds’ specificity profile for ADAMs (Hundhausen, et al., 2003; Ludwig, 
et al., 2005), and the greater specificity for ADAM-10.  
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Figure 1.7: GI254023X (Chemical formula: C21H33N3O4), an inhibitor of 
ADAM-10 activity. This small molecule inhibitor of ADAM-10 binds to the 
pocket of activated ADAM-10, thereby inhibiting the function of ADAM-10.  
 
Notably, ADAM-10 differs from other ADAMs four side-chains, which are 
located in the lining of the S1' pocket, thus causing slight alterations in size 
and surface charge of the pocket (Hundhausen, et al., 2003; Ludwig, et al., 
2005). These surface changes aid in the P1’ phenpropyl substitutent of 
GI254023X attaching enhancing its potency for ADAM-10 S1’ pocket over 
other ADAMs (Ludwig, et al., 2005). Prior research attributes this enhanced fit 
to the compound’s higher potency for ADAM-10 over other ADAMs 
(Hundhausen, et al., 2003; Ludwig, et al., 2005). The involvement of ADAM-
10 in oesophageal cancer and cervical cancer remains unclear. This study 
aims to examine this role by testing the effect of GI254023X inhibitor and two 
compounds, SN-311 and SN-254, which were developed as part of a 
synthetic process to synthesize GI254023X in a laboratory at UCT.   
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1.8 Research rationale 
 
1.8.1 Aim 
Investigate the effects of inhibiting ADAM-10 activity in oesophageal and 
cervical cancer cells using small molecule inhibitors.  
 
1.8.2 Objective 
• To investigate the effect of inhibiting ADAM-10 activity using the small 
molecule GI254023X and its precursors: SN-254 and SN-311 on 
cancer cell survival. 
• To investigate the ability of the small molecule GI254023X and its 
precursors: SN-254 and SN-311 to inhibit epithelial to mesenchymal 
transition in cancer cells. 
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Chapter 2: 
Materials and Methods 
 
 
2.1 Mammalian cell culture 
 
2.1.1 Cell lines 
 
In order to determine ADAM-10 endogenous expression in normal and 
cancerous cell lines grown in culture, a range of cell lines were used. Cervical 
cancer cell line include: HeLa (HPV18 positive), obtained from the American 
Type Culture Collection (ATCC) (Rockville, MD, USA). An oesophageal 
cancer cell line was also used, WHCO5 South African oesophageal cancer 
cells line (Veale and Thornley, 1989). Normal cell lines used included, normal 
lung fibroblast cell line, WI38 (obtained from the ATCC) and the FG0 normal 
skin fibroblast was also assessed (obtained from the Department of Medicine, 
UCT).  
2.1.2 Non-primary cell line growth conditions 
 
All non-primary cancer and normal cell lines used in this study were grown 
and cultured at 37°C within a humidified incubator, supplied with a mixture of 
5% carbon dioxide and 95% air gas. These cell lines were cultured with 
Gibco® Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen, USA) 
containing 10% heat-inactivated foetal bovine serum (FBS), penicillin 
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(100U/mL), and streptomycin (100µg/mL).  
 
2.1.3 Subculturing cells 
 
Cells grown in a 100 mm tissue culture dish to a confluence of 60 – 80% were 
washed with 2 mL of trypsin –EDTA laboratory prepared trypsinisation 
solution, thereafter, the solution was washed off. Thereafter, four millilitres of 
fresh trypsin-EDTA solution was pipetted onto the cells. The culture plates 
where returned to the incubators, left inside to aid in the process of 
trypsinisation. When 70-90% of cells were trypsinised (determined by 
monitoring with use of a microscope), the reaction was stopped with the 
addition of 4 mL of fresh complete media (DMEM, 10% FCS and 1% P/S). 
This cell suspension was transferred into a 12 mL Greiner tube, and 
centrifuged at 250 x g for 3 minutes at room temperature. Post centrifugation, 
this complete media / trypsin-EDTA combined solution was aspirated off, and 
the cell pellet was re-suspended in 1 mL of complete media. Approximately 
150 µL of this cell suspension was then inoculated into 10 mL of fresh 
complete medium within a 100 mm tissue culture dish. 
 
2.1.4 Freezing and thawing cells 
 
A confluent dish (70 – 80% fully grown dish) of cells was trypsinised, 
neutralised with fresh complete media, and following centrifugation, carefully 
removed from this combined trypsin-EDTA / full media solution. These cells 
were then re-suspended in 5 mL of freezing media (70% complete culture 
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media, 20% FCS and 10% dimethylsulfoxide (DMSO)) and 1 mL of this 
solution was added to individual cryotubes. The cryotubes were stored at -
80°C for 24 hours, thereafter transferred to liquid nitrogen for long-term 
storage. 
 
Thawing of frozen stocks (whether from -80°C stocks, or liquid nitrogen) 
involved quickly thawing the cryotube contents in a 37°C water-bath, 
thereafter transferring the cryotube cell suspension contents into a 100 mm 
tissue culture dish containing 10 mL pre-warmed complete media. Cells were 
left in the incubator at 37°C overnight, thereafter change of complete media 
occurred. 
 
2.1.5 Mycoplasma testing 
 
All cell lines were tested twice a year for Mycoplasma contamination. The 
protocol to test involved culturing of cells in penicillin and streptomycin-free 
culture media for 3 days. Continuing with the same culture media conditions, 
cells were then plated onto recently sterile flamed coverslips, and left to settle 
and grow for a further 24 hours. Cells were then fixed and stained with 
Hoechst fluorescent DNA-binding stain for approximately 30 seconds, 
thereafter washed and then mounted with mowiol on microscopy slides. 
Stained slides were visualised on the Zeiss Axiovert 200 Fluorescent 
microscope (Carl Zeiss, Jena, Germany). The absence off small fluorescent 
speckling / spots between the stained nuclei, indicated that cells were 
Mycoplasma- free. 
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2.2 Drug and inhibitor preparation 
2.2.1 GI254023X 
 
GI254023X, a hydroxymate derived inhibitor of ADAM-10, was purchased 
from Tocris Biosciences (Catalogue #3995/1). A 1 mg sample of the drug was 
dissolved into a stock solution concentration of 100 mM in DMSO and stored 
at -20°C (as per manufacturer’s instruction).  
 
2.2.2 Precursor derivatives: SN254 and SN311 
 
During the initial synthesis plan for GI254023X inhibitor, the UCT Chemistry 
Department developed two new precursor derivatives of GI254023X, namely 
SN-254 and SN-311 compounds. Synthesis of SN-254 and SN-311 
compounds were carried out by UCT Chemistry Department.  Briefly, 1 mg 
sample of each drug was dissolved into a stock solution concentration of 100 
mM in DMSO and stored at -20°C. 
 
2.3 Protein analysis 
2.3.1 Preparation of whole cell lysates and protein quantification 
 
After various in-vitro experiments (i.e. detection of epithelial to mesenchymal 
transition markers, or VEGF expression detection post treatment with ADAM-
10 inhibitors), protein was isolated from the plated cells. The existing media 
removed, and cells washed twice with PBS, which was cooled to 4°C. a 
Radioimmunoprecipitation assay buffer (RIPA) containing 0.5 mM PMSF, 
	 33	
complete protease inhibitor cocktail (Roche, Basel, Switzerland), and 50 mM 
NaF, 2mM NA3VO4 to inhibit the action of phosphatases was added to the 
cells. Cells were then scraped using a cell scraper and transferred to a 1.5 mL 
Eppendorf tube. The cell lysate was then subjected to sonication for 10 
seconds, followed by centrifugation at 10000 x g at 4°C for 10 minutes, in 
order to remove any cellular debris. The supernatant was aspirated and 
transferred to a clean Eppendorf 1.5 mL tube. Protein concentration was 
quantified using the Bicinchoninic acid (BCA) Protein Assay Kit (Thermo 
Scientific, USA), as per manufacturer’s instructions. Both the BCA samples 
and the protein samples absorbance was read at 595 nm, and protein 
concentration of the isolated protein samples harvested, was calculated using 
the standard bovine serum albumin concentrations (BSA) readings at 595 nm. 
The isolated protein samples were stored at -80°C for long-term storage.  
 
2.4 Western blot analysis  
2.4.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) and protein transfer 
 
All gels were cast and proteins were separated using the Mini Protean II 
System (BIO RAD). 10 – 35 µg of protein sample size was prepared by 
adding 5X Laemmli loading dye (see solutions) and made up to a specific 
volume with distilled autoclaved H2O. The prepared samples were heat-
denatured at 90°C for 1 minute using a heating block. Heating of the protein 
sample when combined with β-mercaptoethanol and sodium dodecyl sulphate 
(SDS) ensures that the protein sample is denatured, into a reduced state, thus 
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allowing for the successful separation of the proteins present within the 
sample based on their respective size.  
 
Gels were cast in 1.5 mm glass plates using the BIO-RAD system. Resolving 
and stacking gels were prepared as described in table 2.1. The resolving gel 
was poured first, and left to set. Thereafter the stacking gel was cast above 
the set resolving gel, and carefully the 10-well comb was inserted into the 
stacking gel mixture. Prepared protein samples were loaded into the cast 
wells within the stacking gel. A protein molecular weight marker was run 
concurrently with the samples, in order to determine the size of the separated 
proteins (Kaleidoscope, BIO RAD, USA). Protein samples were then 
electrophoresed at 180V for 1.5 hour in 1X Running Buffer (see solutions). 
Following this process, the separated proteins within the resolving gel were 
transferred onto a Hybond™-ECL™ nitrocellulose membrane (Amersham Life 
Sciences, UK) using the wet/tank transfer system (BIO RAD, USA). The 
transfer occurred at 100V for 70 minutes in 1X Transfer Buffer (see solutions).  
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Table 2.1: Solutions with specified volume as per gel condition for Western 
blot analysis. 
Resolving gel (cast in 1.5mm glass plate): 
 
Contents:  12% 10% 7.5% 15% 
dH2O 2150 µL 2850 µL 7280 µL 3300 µL 
1M Tris pH8.8 3750 µL 3750 µL 3750 µL 3900 µL 
10% SDS 50 µL 50 µL 150 µL 150 µL 
30% Acrylamide/ bis 4000 µL 3300 µL 3750 µL 7500 µL 
10% Ammonium 
persulphate (APS) 
50 µL 50 µL 75 µL 150 µL 
TEMED*  5 µL 5 µL 7.5 µL 15 µL 
 
Stacking gel (cast in 1.5mm glass plate): 
Contents: 4% 
dH2O 3650 µL 
1M Tris pH6.8 625 µL 
10% SDS 50 µL 
30% Acrylamide/ bis 650 µL 
10% Ammonium 
persulphate (APS) 
60 µL 
TEMED* 6 µL 
*(N,N,N’,N’tetramethylethylenediamine) 
 
2.4.2 Immunoblotting and chemi-luminescent detection 
 
Following the transfer of the protein samples onto the nitrocellulose 
membrane, the membrane was blocked in 5% low fat milk dissolved in Tris-
buffered saline with 0.1% Tween (TBST) for 1 hour at room temperature. 
Thereafter, the membrane was probed with the specific primary antibody at 
4°C over night with agitation. Post primary antibody incubation, the membrane 
was washed three times with TBST for 10 minutes each, thereafter the 
	 36	
nitrocellulose membrane had horseradish peroxidase-conjugated secondary 
antibody added onto it for 1 hour at room temperature with agitation. 
Following the incubation of the membrane with the secondary antibody, 
excess secondary antibody was removed with three 10 minute TBST washes. 
The protein bands were detected using the LumiGLO or LumiGLO reserve 
chemiluminescent substrate system (KPL Inc.). For detection procedure, 
AGFA CU-BR Medical X-ray film (AGFA, Belgium) were exposed onto the 
membrane. Thereafter, the X-ray film was developed until the band(s) of 
interest were seen, before the X-ray film was fixed in a fixative reagent.  
 
2.4.3 Antibody concentrations and conditions 
 
Below, is a table summarising the blocking conditions for all primary 
antibodies used, along with their corresponding secondary antibody 
conditions (table 2.2) 
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Table 2.2: Blocking and immunoblotting conditions for primary and secondary 
antibodies 
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2.4.4 Densitometry analysis 
 
Once X-ray radiographic detection (using AGFA radiofilm) of membranes 
were performed, the developed band intensities of proteins probed were 
quantified by densitometry using ImageJ software, following the 
manufacturer’s instructions. The protein expression of each band was 
quantified relative to the intensity to β-tubulin or GAPdH bands (which served 
as the loading control).  
 
2.4.5 Stripping and reprobing blots 
 
To re-probe the membrane for another protein, the membrane was stripped 
using 10% acetic acid for 30 minutes at room temperature with agitation. 
Following stripping, the membrane was then washed 4 times with TBST for 5 
minute intervals at room temperature each time with agitation. Thereafter, the 
membrane was again blocked in 5% milk, and primary antibody conditions as 
stipulated in table 2.2 were applied. 
 
2.5 Drug efficacy assessment 
2.5.1 MTT EC50 determination assay 
 
The EC50 value of GI254023X, and the two newly synthesized precursors, 
SN-254 and SN-311 were determined in a two normal cell lines (FG0 and 
WI38), and two independent cancer cell lines, namely HeLa cervical cancer 
cell line and WHCO5 oesophageal cancer cell line respectively.  Cells were 
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grown in complete media (DMEM, 10%FCS, 1%P/S) and seeded at a density 
of 1000 cells per well for HeLa, and 3000 cells per well for WHCO5, FG0 and 
WI38 cells, and plated into a 96-well tissue culture plate.  Cells were treated 
the following day with varying concentrations of the small molecule inhibitors 
of ADAM-10 (0, 10, 50, 75, 100, 200, 300 and 400 µM), all performed in 
triplicate.  24 hours after drug treatment of the individual cell lines, 10 µL MTT  
reagent (Sigma) was added to each well, and four hours later the crystals 
formed were solubilised by the addition of Solubilisation Solution Reagent (10 
% SLS in 0.01 M HCl). Absorbance readings were measured at 595nm the 
following day using a BioTek microplate spectrophotometer (Winooski, VT, 
USA). The EC50 determined assay curves were generated with use of 
GraphPad 6.05 Prism (Mac compatible edition).  
 
2.5.2 Anchorage-dependant (MTT) proliferation assay 
 
Cell growth and death as a result of either ADAM10 knockdown transfection 
assays or treatment with GI254023X, SN-311 and SN-254 was numerically 
determined using the MTT proliferation assay, which analysis cell viability and 
proliferation by the addition of a yellow reagent, MTT (3-(4,5-dimethylthiazole-
2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma). MTT is a positively charged 
tetrazolium salt, which readily penetrates the cell membrane of viable cells, 
and in the process the salt is reduced to a purple formazan product by means 
of the active metabolism of the viable cells, it penetrates (Berridge and Tan, 
1993). Furthermore, the MTT reagent is solubilised by the addition of a 
solubilisation reagent (10 % SLS in 0.01 M HCl) and quantified by reading 
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absorbance at 595nm using a BioTek microplate spectrophotometer 
(Winooski, VT, USA). The proliferation assay was performed over a five-day 
period. HeLa cervical cancer cell line and WHCO5 oesophageal cancer cells 
were seeded into 96-well tissue culture plates at 1000 cells per well. The 
EC50, 2X EC50 and the volume required to dissolve the drug at 2X EC50 in 
DMSO (control) was selected for each of the small molecule inhibitors and 
treated to each cell line for each day, and treatment was performed in 
triplicate. On each day that the assay was performed, 10 µL of MTT was 
added to each of the treated wells, thereafter, 4 hours later, 100 µL of 
solubilization solution was subsequently added. The next day the 96-well 
tissue culture plate was read at 595 nM using a BioTek microplate 
spectrophotometer (Winooski, VT, USA).  
 
2.5.3 Clonogenic colony formation assay 
 
Clonogenic colony formation assay is described as an in vitro cell survival 
assay, This assay monitors the ability of a single cell to grow into a colony of 
at least 50 cells. This assay is widely used to assess the number and size of 
cancer cell colonies that remain post cytotoxic agent administration / 
treatment. Briefly, 1000 cells were seeded into each well within a 6-well plate.  
Both HeLa cervical cancer cell line and WHCO5 oesophageal cancer cell line 
were seeded to 1000 cells per 6-well plate, plated in triplicate, and treated 24 
hours later with EC50 value, 2X EC50 value of each of the small molecules 
under investigation individually per cell line, as well as the equivalent volume 
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of DMSO required to dissolve 2X EC50 concentration of each drug, serving as 
a control variable. The treated cells were left to grow in the incubator at 5% 
CO2, 37°C for a period of 9 days. Thereafter, cells were stained with 0.5% 
crystal violet staining solution (see solutions), and cell colonies formed were 
quantified under the stereomicroscope. High definition (HD) resolution 
photographs were taken of each well, and colonies were quantified using the 
ColonyArea ImageJ Plugin, as described by Guzman and colleagues (2014). 
Plating efficiency and survival fraction was calculated using the following 
equations:  
• Plating efficiency %: (PE%) = number of colonies / number of cells 
plated x100 
• Survival fraction %: (SF%) = PE of treated sample / PE of control x100 
• Cell survival = number of counted colonies / [number of seeded cells x 
PE control / 100] 
 
2.6 ADAM10 functional assay 
2.6.1 Human CX3CL1 fractalkine immunoassay – enzyme linked 
immune-sorbent assay (ELISA) 
 
The CX3C chemokine fractalkine (CX3CL1) exists both as a membrane 
protein, enhancing cell-cell adhesion, as well as a soluble molecule form, 
aiding in chemotaxis (Hundhausen, et al., 2003). The trans-membrane 
CX3CL1 is converted into its soluble form by the process proteolytic cleavage 
(shedding). Cleavage of the 95 – 100 kDa type 1 transmembrane form of 
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fractalkine into its soluble 60 – 80 kDa form, is conducted by ADAM10 
(Hundhausen, et al., 2003).  
This assay, the Quantikine® ELISA Human CX3CL1/ fractalkine Immunoassay 
(catalogue number: DCX310, R&D Systems, USA), utilizes the quantitative 
sandwich enzyme immunoassay technique. Plates were precoated with a 
human fractalkine monoclonal antibody. Both standards (employed within this 
kit) and samples tested were collected according to the manufacturer’s 
requirements. Briefly, 100 µL of the Assay diluent RD1-88 (kit provided) was 
pipetted into each of the wells used in the 96-well plate provided. Thereafter 
within 15 minutes, a 100 µL of the standard control and tested samples 
collected post EC50, 2X EC50 and DMSO (control) treatment of all compounds 
assessed in HeLa and WHCO5, were added to the wells, and left to incubate 
for 3 hours at 4°C.  
 
Post washing away any unbound substances with the washing buffer (kit 
provided), 200 µL of the cold enzyme-linked monoclonal antibody specific for 
human fractalkine was added to each of the wells within the 96-well plate, and 
left to incubate for a further 1 hour at 4°C. Following another wash to remove 
any unbound antibody-enzyme reagent, 200 µL of a substrate solution (kit 
provided) was added to each of the wells. At this stage, the plate was stored 
away from light and left to incubate at room temperature for 30 minutes. 
Lastly, 50 µL of a kit provided stop solution was added to each well, resulting 
in a colour change, with intensity of the colour change correlating to the 
amount of fractalkine bound within the initial step. This colour intensity was 
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measured at 450 nm, and corrected to 570 nm, as per manufacturer’s 
instructions, using the BioTek microplate spectrophotometer (Winooski, VT, 
USA). 
 
2.7 Microscopy and immunofluorescent analysis 
2.7.1 Immunocytochemistry detection in cell lines – actin staining 
 
250000 HeLa cervical and WHCO5 oesophageal cancer cells were plated and 
left to grow on flamed sterilised glass coverslips in a 6-well tissue culture 
treated plate in complete media (DMEM, 10%FCS, 1%P/S). The following 
day, once the cells had settled on the coverslips, they were treated with EC50, 
2X EC50 of GI254023X, SN-254 and SN-311. For control variables, equivalent 
volumes of DMSO required to dissolve 2X EC50 of each small molecule 
inhibitor was used.  
 
Following treatment of the cells, the treated media was removed and the cells 
were washed with PBS, thereafter the cells were fixed with 4% 
paraformaldehyde (PFA), which was then followed by three intervals of 5 
minute washes in PBS.  Following fixation, the treated cells were 
permeabilised with 0.5% Triton-X 100, and subsequently washed in PBS for 5 
minutes.  The permeabilised cells were then quenched with 50mM NH4Cl 
made up in PBS for 5 minutes, thereafter blocking of the quenched cells were 
performed using 0.2% gelatin dissolved in PBS for 30 minutes at room 
temperature. After blocking, cells were incubated with fluorescently labelled 
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50ng/mL Phalloidin-Tetramethylrodamine B isothiocyanate (Sigma-Aldrich) in 
0.2% gelatin dissolved in 1X PBS, and incubated for 45 minutes at room 
temperature, by means of inverting the coverslips onto 100µl drop of the 
antibody dilutions. All incubation periods were conducted within a humidifying 
chamber in the dark. Following phalloidin incubation, the coverslips were 
washed 3 times for 5 minute intervals with 1X PBS. Thereafter, the cell nuclei 
were stained with 100ng/ml Hoechst staining in 1X PBS for 10 minutes at 
room temperature. The coverslips were finally washed 1X PBS at room 
temperature and mounted onto slides with Mowiol® -88 (Polysciences Inc., 
USA). Slides were stored at 4°C in a dark, slide storage chamber for long-
term storage. Images of the slides were captured using a Zeiss inverted 
fluorescence microscope under 100 X oil immersion.  
 
2.7.2 Phase- contrast microscopy 
 
Phase contrast microscopy technique was used to capture any possible 
morphological changes associated with transformation and the effect of 
ADAM-10 inhibition in HeLa and WHCO5 cell lines post treatment with 
GI254023X, (and also with SN-254 and SN-311. Cells were plated onto 
sterilized cover slips in 60 mm dishes, and allowed to settle overnight 
following adherent growth conditions. The next day, cell lines were treated 
with either one of the compounds, at either the EC50, 2X EC50 concentrations, 
or with DMSO volume equivalent to 2X EC50 required volume to dissolve the 
drug. 48 hours after treatment, the various cell lines were fixed in 4% 
paraformaldehyde for 20 minutes at room temperature and mounted on slides 
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using Mowiol® -88 (Polysciences Inc., USA). Slides were stored at 4°C in a 
dark, slide storage chamber for long-term storage. Cells were viewed under 
visual light and phase contrast, and numerous pictures were taken using a 
standard fluorescence microscope.  
 
2.8 Monitoring cellular killing effects 
2.8.1 PARP1 (Poly (ADP-Ribose) Polymerase 1) detection assay 
 
Poly(ADP- Ribose) polymerase (PARP), is a well known caspase cleaved 
substrate (Bock and Chang, 2016; Kotsopoulos, 2016), therefore induced 
cleavage of its protein, indicates that the cell is undergoing apoptosis. PARP 
is therefore involved in regulating cellular responses to stresses, which are 
induced by DNA damage response (DDR), unfolded protein response (UPR), 
and cytoplasmic stress response (Bock and Chang, 2016). 350 000 HeLa and 
WHCO5 cancer cells were seeded per 60mm dish into 4ml of complete media 
(DMEM, 10%FCS, 1%P/S) and incubated overnight at 37°C.  The following 
day, treatments with GI254023X, SN-311 and SN-254 were performed with an 
EC50 and a 2X EC50 concentration value of the compounds. DMSO only 
treatment served as the control variable for each of the small molecule 
treatments. 48 hours after treatment, cells were harvested by collecting both 
adherent and floating cells (within the media). The initial step involved 
aspirating the media bathing the treated cells, and decanting it into a sterile 12 
mL tube.  The 12 mL tubes were centrifuged at 10 000 RPM to harvest the 
floating cells. After suctioning off gently the supernatant after centrifuging the 
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12 mL tube, the formed pellet of floating cells was gently washed and re-
suspended with PBS and placed in sterile 1.5 mL eppendorf tube. Thereafter, 
another round of centrifugation was performed with the 1.5 mL eppendorf 
tubes at 10 000 RPM for 15 minutes at 4°C.  The PBS was removed and the 
eppendorf tubes were placed on ice.   
The remaining adherent cells to the dishes were harvested using RIPA mix 
and a cell scraper as described in section 2.3.1.  Following the process of 
sonication and centrifugation, the cell lysate of both adherent and floating 
cells supernatant was transferred into a clean 1.5ml eppendorf tube and 
proteins were quantified as described in section 2.3.1.  PARP-1 cleavage was 
detected via western blot analysis and radiographically viewed with LumiGLO 
chemiluminescent substrate system (KPL Inc.). The presence of a 89kDa 
cleaved PARP band from the 116kDa full length PARP band, was an 
indication of apoptotic activity.  
	
2.8.2 Caspase GLO 3/7 Apoptosis assay 
 
Caspases 3 and 7 are known mediators of the apoptosis. Their enzymatic 
activity levels can be determined using a luminogenic substrate system, 
whereby the luminescence produced in this activity assay is proportional to 
caspase activity, and thus apoptosis. The extent of apoptotic activity was 
determined by measuring the Caspase-3/7 activity, using the Caspase-Glo® 
3/7 Assay (Promega), according to the manufacturer’s instructions. Cells were 
seeded into tissue culture 96-well plates, at a final volume of 90 µL with a cell 
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concentration value of 8000 cells/well. The following day, these cells were 
treated either with GI254023X, SN-311 or SN-254 at EC50 and 2X EC50 
concentrations respectively at a final volume of 10 µL. DMSO only treatment 
served as the control variable for each small molecule treatments. 48 hours 
after treatment, 100 µL of Caspase-Glo 3/7 reagent was added to each well. 
The plate was left at room temperature for 1 hour, protected from light. 
Thereafter, 100 µL of this cell/Caspase 3/7 suspension was transferred to a 
white 96-well plate (Nunc, Rochester, NY, USA). Luminescence was 
measured and quantified using the Glomax 96 Microplate Luminometer 
(Promega).  
 
2.9 Cellular adhesion assays 
2.9.1 Fibronectin-coated adhesion assay. 
 
All cell lines (HeLa and WHCO5) were treated with GI254023X, SN-311 and 
SN-254 at concentrations of EC50, and 2X EC50, and at 0 µM (served as the 
control – DMSO only treatment). In a 96 well plate, 40 µL of 20µg/mL 
fibronectin was coated on the base of each well and incubated at 4ᵒC 
overnight. Post fibronectin coating, all wells were washed twice with 200 µL 
wash buffer (0.1% BSA in antibiotic and serum free media) and blocked in 
200 µL binding block buffer (0.5% BSA in DMEM only) for 1 hour at 37ᵒC. The 
binding block buffer was discarded with the addition of 200 µL wash buffer 
and incubated on ice for 10 minutes. A total of 8x104 cells was plated into 
each of the 6 well plate per treatment and incubated at 37 ᵒC for 30 minutes, 
with gentle tapping every 3 minutes. The unbound cells were rinsed away by 
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200 µL wash buffer. The remaining bound cells were fixed in 50 µL 4% 
paraformaldehyde for 15 minutes at room temperature. Thereafter the plate 
was again rinsed with 200 µL of washing buffer per well. The wells were then 
stained with 60 µL crystal violet (5mg/mL in 2% EtOH) for 10 minutes at room 
temperature. Excess crystal violet was rinsed off with 100 µL dH2O and left to 
dry overnight in a fume hood. The next day, 50 µL 2% SDS was added to 
solubilise stained cells and a colorimetric intensity was analysed on a 
microplate reader at 595 nm.  
 
2.9.2 Non—coated adhesion assay 
 
All cells (both HeLa and WHCO5) were seeded and pre-treated with the 
established EC50 and 2X EC50 value of GI254023X, SN-311 and SN-254 
compounds respectively. DMSO only treatment served as the control variable 
for each small molecule treatments. Thereafter, treated cells were trypsinised 
and recounted to be seeded to a total number of 5x104 cells within a total 
volume of 500 µL and added into a 24-well plate, in which the cells were 
incubated for 1 hour at 37ᵒC. Thereafter, all media was removed from these 
wells. Half the wells of each treatment were washed with 300 µL of PBS, 
whilst the remainder of the wells remained unwashed, hence served as a total 
cell control. Then both washed and unwashed wells were fixed with 100 µL of 
4% paraformaldehyde for 15 minutes and stained with crystal violet for 5 
minutes. Thereafter, all the wells were rinsed three times with dH2O (to 
eradicate excess crystal violet), and allowed to dry overnight at room 
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temperature. A range of fields of view was reviewed for each treatment and 
subsequently calculated in relation to the unwashed wells accordingly.   
 
2.10 Motility assays 
 
2.10.1 Transwell migration assay 
 
Transwell migration assays are commonly used for studying motility of 
metastatic cancer cells. The principle behind this assay is based on two-
medium containing chambers, employing a permeable layer of support 
(usually tissue-culture treated microporous membrane) through which 
metastatic cancer cells transmigrate. Each compartment mimics different 
microenvironments for cell survival.  
 
A Transwell inserts with 8 µM pores were used in this assay (Greiner bio-one, 
Solingen, Germany). Cells were plated at 3x105 cells per 60 mm dish. The 
following day, the cells were treated with the various compounds under 
review, at concentrations of the determined EC50 and 2X EC50 value. DMSO 
only treatment served as the control variable for each small molecule 
treatments. 24 hours after treatment, treated cells were trypsinised and 
counted so that 2.5 x 105 cells were re-plated in triplicate within a 24-well plate 
in 0.5 mL of 1% FCS-containing media onto the porous membrane of the 
inserted chamber (within the upper chamber), allowing for vertical directed 
migration of the cells through the pores of the membrane into the lower 
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chamber containing a chemo-attractant agent (higher serum concentration of 
20% FCS-containing media).  
 
These cells were incubated at 37°C and allowed to migrate through the 
porous membrane to the underside of the insert for a 24 hour period. After the 
24-hour incubation period, cells, which had not migrated, and found on top of 
the membrane, were removed with a cotton swab. Motile treated cells, which 
moved to the underside of the membrane, were fixed in 1 mL of methanol for 
a 5 minute period, thereafter was stained with 1 mL of crystal violet (0.2% w/v 
in 2% methanol) for 5 minutes. The inserts were then rinsed five times with 
dH2O, and at every interval, cotton swabs were used to ensure that the sides 
and edges of the inserts were cleaned and dried properly.  
 
Along with every treatment condition assessed, which was performed in 
triplicate, and repeated independently twice, a fourth chamber of cells were 
plated, and served as a total cell number control between the various drug 
treatment conditions applied. The cells plated in this fourth chamber were not 
removed with a cotton swab, instead were stained on either side of the 
membrane with crystal violet (0.2% w/v in 2% methanol) for 5 minutes.  
 
The total number of migrated cells was normalized for each condition to the 
control insert (the 4th chamber of each drug treatment condition), which was 
then further normalized to the control –DMSO only treated wells, as DMSO 
treatment served as the control variable for each small molecule treatments 
(as each of the drugs assessed were dissolved in DMSO). The stained 
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membranes were left to dry overnight at room temperature, following which 
the stained cells were viewed under a microscope and images were taken in 
ten random fields under view. The cells in each of the fields were counted and 
quantified to determine the number of migrated cells using ImageJ software. 
Furthermore, an additional quantitation method was applied whereby the 
stained cells were solubilised with 50% acetic acid and the absorbance read 
at OD595.  
 
 
Figure 2.1: Transwell migration assay (Boyden chamber assay). Migration of a cell 
through a pore in the membrane is depicted (Kramer, et al., 2013).  
 
2.10.2 Transwell matrigel invasion assay 
 
To analyse carcinoma invasion, HeLa cervical and WHCO5 oesophageal 
cancer cell lines respectively, were pre-treated with the GI254023X, SN-311 
and SN-254, at the individual determined concentrations of EC50, and 2X EC50 
per drug. 24 hours after treatment, treated cells were trypsinised and counted 
so that 2.5x105 cells were re-plated in triplicate within 0.5 mL of 1% FCS-
containing media onto the membrane of the inserted matrigel-coated chamber 
(Corning Matrigel Invasion Assay kit, USA).  
 
The matrigel serves as a basement membrane, which functions as an 
extracellular matrix. The matrigel chambers were initially incubated in a 37°C 
violet), and the number of cells that have migrated is determined.
For the second method, the migrated cells are stained fluorescent-
ly, removed from the membrane by dissociation (using cell
dissociation agents such as trypsin) and quantified using a
fluorescent reader. Alternatively, dark colored porous membranes
are available, which block light transmission (FluoroBlok, Becton
Dickinson) from unmigrated cells. The detection of the migrated
labeled cells is therefore simplified and there is no need to remove
the remaining cells from the top-side of the membrane. The
advantages are the availability of different cell culture inserts and
sizes, the relative easiness of the experimental setup and a short
lasting medium/cytokine/chemokine gradient between the upper
and lower culture medium reservoir. This assay is most frequently
used to assess cell migration. Except the cell culture inserts no
special equipment is needed. The disadvantages are that it is an
endpoint assay; the optimal time of analysis has to be determined
individually for each cell type tested. If histological cell staining
procedures are used there are several precautions to make: non-
invaded cells, which stayed on the upper side of the transwell
insert, have to be removed prior to staining of the invasive cells at
the bottom of the membrane. This is commonly done by getting rid
of the cells with a cotton swab, which often turns out difficult, non-
quantitative and of variable success. We strongly recommend
using fluorescent dyes, lysing the cells and quantifying them in a
plate reader or to rely on the light blocking membranes and
quantify migrated cells without lysis. The transwell migration
assay is suitable for many different cell types including epithelial
[35], mesenchymal [36] and brain [37] cancer cell lines as well as
many primary cells from all three germ layers. Conventional cell
culture inserts or whole transwell migration kits are commercially
Fig. 2. Schemes of commonly used migration assays. An overview of the technical setup is schematically drawn for each assay and a close-up view is given right to it (inside
the big circles). Arrows indicate the direction of cell movement. Hatched areas symbolize ECM. (A) Transwell migration assay (Boyden chamber assay). Migration of a cell
through a pore in the membrane is depicted. (B) Wound healing assay. Scratching off cells from a dense monolayer produces a cell free area. This is often performed with a
vertically held pipette tip. The close up view depicts that cells can be seeded on plastic or glass surfaces or on ECM coated surfaces (hatched areas). (C) Cell exclusion zone
assay (Platypus migration assay). The cell free area is produced by cell exclusion upon seeding by using silicone stoppers, which are removed before starting the experiment.
(D) Fence assay. Cells are seeded inside a ring-shaped plastic device, which is placed on a cell culture dish. After cell attachment the ring is removed and the cells migrate from
the circular area to the non-covered surrounding. Migration is measured as the increase of the area covered by moving cells. (E) Microcarrier bead assay. Microcarrier beads
are coated with cells to confluence and subsequently the cell-coated beads are placed onto cell culture dishes and incubated. Cells from the microbead attach to the plate
surface and perform radial movement, the area of which can be measured. (F) Spheroid migration assay. Multicellular spheroids of a certain cell type are produced and put
onto conventional tissue culture dishes. The spheroids attach to the surface and cells start moving concentrically outward. The increase in the spreading area can be measured
over time. (G) Horizontal capillary assay (Dunn chamber, Zigmond chamber). The cells migrate along a stable gradient of a chemoattractant within a thin bridging capillary.
None or special surface coating can be used (hatched areas, as in B and C). (H) Capillary tube migration assay. In small capillaries, leukocytes migrate out of the ‘‘buffy coat
area’’ into serum. The migration capacity of the cells can be directly measured by determining the position of the migration front in correlation to the starting line. (I)
Leukocyte migration agarose technique assay. Holes of a defined diameter and distance are punched out of agarose gels; in one of these holes leukocytes are seeded, which
migrate underneath the agarose layer toward a medium reservoir containing a chemoattractant (or repellent), whereas migration toward medium alone serves as control. The
area of migration (dotted line) is visible and the difference in migration distance is determined. (J) Single cell motility assay. Normal tissue culture plates are preincubated
with colloidal gold particles and thereafter cells are seeded at low density above. On their way across the plate, the cells clear the gold particles on their routes leaving bright
tracks behind, which can be measured.
N. Kramer et al. / Mutation Research 752 (2013) 10–24 13
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incubator for 4 hours to allow for the matrigel coated membrane to solidify. 
Thereafter 1 mL of complete media containing 20% FCS was added to each 
12 well. Then, 5x105 of recently suspended treated cells were added into the 
matrigel chamber within a volume of 500 µL of 0.5% FCS media. Cells were 
incubated at 37°C, 5% CO2 for 24 hours to allow for invasion of the cancer 
cells, moving through the matrigel membrane toward the underside of the 
matrigel chamber, following which, the matrigel member chambers were fixed 
and stained with crystal violet as mentioned 2.10.1. Random image fields of 
the matrigel depicting invaded cells were captured (10 images per condition) 
via the microscope camera, counted and analysed accordingly.  
 
2.11 Statistical analysis 
 
All experiments were performed in triplicate and repeated at least two 
independent times. Results are presented as the mean value ± standard error 
of mean (SEM) unless stated otherwise. The Student’s t-test (paired and 
unpaired) was applied to calculate statistically significant differences between 
samples. A two-tailed distribution was used. Statistical significance was 
defined using a type I error or p-value of 0.05 where the p-value is the 
probability of rejecting the null hypothesis when it is assumed to be true. All 
calculations were performed in Microsoft Excel for MAC 2011 and GraphPad 
Prism MAC compatible (GraphPad Prism 6.05 Software, La Jolla, CA, USA).  
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Chapter 3: 
Investigating the effects of GI254023X, SN-311 and SN-254, on cancer cell 
survival and proliferation. 
 
 
 
3.1 Introduction 
 
The ‘magic bullet’ concept, formulated first by Paul Ehrlich in the late 1800s, 
formed the basis of current direct chemical therapy (Imai and Takaoka, 2006). 
Ehrlich postulated the ability of a chemical to specifically target a given 
microorganism (Imai and Takaoka, 2006). Since the publication of his theory, 
targeted drug therapeutics have been combined with established cancer 
treatment regiment affecting specific molecular biomarkers (Imai and Takaoka, 
2006; Charlton and Spicer, 2016). The development of ground-breaking cancer 
therapeutic approaches, includes a monoclonal antibody (mAbs) molecular 
targeting technique, able to induce a specific mechanism of action by targeting a 
tumour-selective cell-surface protein (Imai and Takaoka, 2006). These novel 
treatment techniques also include small-molecule inhibitors, peptide mimics and 
antisense nucleotides (Imai and Takaoka, 2006).   
 
The discovery of new small molecule inhibitors targeting cancer has 
revolutionised prevailing treatment approaches (Hoelder, Clarke and Workman, 
2012). The historical use of cytotoxic chemotherapy where a one-size fits all 
therapeutic approach on the systemic application to disrupt cancer cell mitosis, is 
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often associated with broad tissue and organ based toxicities (Charlton and 
Spicer, 2016; Hoelder, Clarke and Workman, 2012).  
 
Research in molecular targeted cancer therapy is generating treatment regimens, 
which may have positive impacts in the lives of many cancer patients. Initial 
advancement into targeted therapy development was based on the treatment of 
haematologically derived malignancies (Charlton and Spicer, 2016). The first 
reported cancer-targeted monoclonal antibody therapeutic was rituximab. 
Rituximab, an antibody to the antigen CD20 on the B-cell, was used to treat B 
cell non-Hodgkin’s lymphoma (Druker, et al., 2001; Charlton and Spicer, 2016). 
Further molecular studies into another blood based malignancy, chronic myeloid 
leukaemia (CML), identified a BCR-ABL translocation between the chromosomes 
9 and 22, signalling the overexpression of active tyrosine kinases (Druker, et al., 
2001; Charlton and Spicer, 2016). Imatinib, the first FDA approved small 
molecule inhibitor target therapy for cancer was developed to bind and block the 
mutated tyrosine kinase activity  (Charlton and Spicer, 2016). 
 
ADAM-10 is an established biomarker in neurodegenerative diseases 
(Hoettecke, et al., 2010), and has been implicated in the involvement of cancer 
and pro-inflammatory activities (Hoettecke, et al., 2010). Therefore, the targeting 
and direct inhibition of ADAM-10 is seen as a promising strategy to target cell 
proliferation, migration and invasion in cancer (Hoettecke, et al., 2010; Ludwig, et 
al., 2005).  
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ADAM-10 small molecule inhibitors have come under investigation, with several 
of them belonging to the peptidomimetic hydroxamic acid inhibitors for 
metalloproteinase (Hoettecke, et al., 2010; Ludwig, et al., 2005). Among these 
hydroxamate inhibitors, are batimastat and marimastat, which exhibit a lack of 
selectivity due to their ability to inhibit a broad spectrum of metalloproteinases; 
thereby dramatically affecting its potency (see Figure 3.1 A, B, C) (Hoettecke, et 
al., 2010; Ludwig, et al., 2005).  
 
Figure 3.1: ADAM inhibitors. A- Batimastat; B- Marimastat; C- GI254023X 
(Hoettecke, et al., 2010). 
 
Glaxo Smith Kline described a newly synthesized targeted inhibitor of ADAM-10, 
namely GI254023X (see Figure 3.1C). The molecular modelling of GI254023X 
showed a P1’ position alteration within the pseudopeptidic part of the molecule 
when compared to Batimastat and Marimastat (Figure 3.1A-B), therefore differing 
from a broad- spectrum of metalloproteinase inhibitors, due to a large 
hydrophobic substitution (Ludwig, et al., 2005). The lipophilic substitution within 
this P1’ position of GI254023X enhanced the compounds’ specificity profile for 
ADAM-10 (Hundhausen, et al., 2003; Ludwig, et al., 2005). 
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differentially mediate various shedding events, depend-
ing on the substrate, cell type and stimulatory conditions. 
Therefore, it is advantageous to increase the specificity of 
the inhibitors for the selected ADAM. We have recently 
characterized the reference inhibitor GI254023X (sub-
stance 3) for ADAM10 (IC 50 = 5.3  ! M ) with only minimal 
effect on ADAM17 (IC 50 = 541  ! M ), while no additional 
ADAM was affected ( fig. 1 )  [5, 6] . An inhibition of the 
metalloproteinases-9 and -13 was observed at a low mi-
cromolar level, but it did not interfere with the investi-
gated shedding events  [6] ; however, a soluble amyloid pre-
cursor protein- " reduction to 30% was detected in neu-
roblastoma cells at a concentration of 10  ! M  [7] . This 
inhibitor has served in a number of collaborative studies 
as an important tool to observe cell proliferation and mi-
gration in models of cancer and inflammation  [1] . Unfor-
tunately, this reference inhibitor is no longer available 
from commercial suppliers.
 Glaxo Smith Kline disclosed a synthesis of GI254023X 
(substance 3) in a patent application ( fig. 2 )  [8] . The orig-
inal synthesis started with a LiNEt 2 -mediated alkylation 
of the enantiomerically pure  R -[-]-hydroxybutyrate (sub-
stance 4) with cinnamylbromide, followed by a subse-
quent hydrogenation over palladium on carbon (Pd/C) to 
obtain  R -methyl-2-[ R -1-hydroxyethyl]-5-phenylpentano-
ate (substance 6). The following saponification to  R -2-[ R -
1-hydroxyethyl]-5-phenylpentanoic acid (substance 7) 
was performed with 1  M NaOH in a mixture of tetrahy-
drofuran (THF)/MeOH. The hydroxylamine moiety was 
introduced using 2-tetrahydropyranyl oxyamine in com-
bination with 1-ethyl-3-(3-dimethylaminopropyl)car-
bodiimide (EDC). Activation of the hydroxyl group with 
methanesulfonyl chloride and the subsequent cyclization 
resulted in the  # -lactam ring (substance 9). Basic cleavage 
of the  # -lactam ring and the formylation of the amine 
with a mixed anhydride provided the key building block 
of GI254023X with an 81% yield. The introduction of  L -
 tert -leucine methylamide (substance 21), which was pre-
pared in 2 steps from Boc- L - tert -leucine with  N -nitroso-
bis[2-oxopropyl]amine reagent, 1-hydroxybenzotriazole 
(HOBt) and substance 11, led to substance 12 with a mod-
erate yield of 36%. The final deprotection of substance 12 
by acetic acid in water provided GI254023X with an over-
all yield of 20%  [8] .
 An upscaled synthesis of substance 3 with an overall 
yield of a mere 20% implies high costs for reagents and 
starting materials. Furthermore, the tetrahydropyran 
(THP)-protected intermediates (substances 8–12) do not 
absorb at 254 nm wavelengths, which impairs their han-
dling by standard TLC and HPLC equipment. The unde-
fined stereogenic center of the THP results in diastereo-
meric intermediates, complicating the analysis and puri-
fication even further. An upscalable synthesis is thus 
required for this reference inhibitor as single-batch iden-
tity is essential for the reproducibility and comparability 
of animal trials. Therefore, our aim was to improve the 
synthesis of substance 1 with respect to its costs, yields 
and detectability. 
 Material and Methods 
 Synthesis 
 The first 3 steps of the improved synthesis followed the Glaxo 
synthesis  [8] . However, the THP-hydroxylamine was replaced by 
benzyl hydroxylamine, which was introduced using EDC in a di-
methylformamide (DMF)/water mixture with a good yield (75%) 
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Given the interest to determine the effects of specifically targeting ADAM-10, we 
were interested in determining the effects of GI254023X and other similar 
molecules on markers of tumorgenicity in cancer cells. Whilst synthesizing 
GI254023X, UCT Chemistry Department was able to generate two molecules en 
route to synthesizing GI254023X, named SN-254 and SN-311 respectively. A 
comparison of GI254023X and its two precursor derivatives is shown in: figure 
3.2, and table 3.1. 
 
 
Figure 3.2: Structural comparison between GI254023X, SN-254 and SN-311. 
GI254023X molecular structure and the two newly synthesized molecules, SN-
254 and SN-311, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. SN-254 2. SN-311 3. GI254023X 
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Table 3.1: Structural difference between GI254023X, SN-254 and SN-311. 
(Nair, S, 2015 unpublished data). 
 
 
 
 
In this study we investigated whether the two newly synthesized small molecules, 
SN-311 and SN-254, have effects on the biology of cancer cells in a similar 
manner as GI254023X. Experiments to determine whether SN-254 and SN-311 
inhibited ADAM-10 associated activities and other markers of tumorigenicity of 
cancer, which GI254023X is known to inhibit, was performed.   
 
 
 
 
 
 
 
 
 
 
 
ADAM-10 inhibitors: SN-254 SN-311 GI254023X 
i. At C3 side chain 
length: 
1 carbon chain 3 carbon chain 3 carbon chain 
ii. Phenyl ring position: Positioned 
closer to main 
chain 
Positioned 
further from 
main chain – 
similar to 
GI254023X 
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3.2 Results 
3.2.1 The effect of GI254023X, SN-311 and SN-254 on cancer cell growth 
and proliferation 
 
The small molecule inhibitor of ADAM-10, GI254023X, and two newly 
synthesized small molecules, namely SN-254 and SN-311, were tested in 
biological assays to determine their effect in inhibiting cell growth and 
proliferation. EC50 values of all three small molecules was determined in a panel 
of cell lines, including cervical (HeLa), oesophageal (WHCO5) cancer and in non-
cancer cell lines (WI38 and FG0). The EC50 or effective concentration value was 
determined using GraphPad Prism. This program proximate’s this EC50 curve by 
means of applying 4 parameter non-linear logistic equation, called the Hill 
equation (Gadagkar and Call, 2015). The HeLa cervical cancer cell line, and the 
WHCO5 oesophageal cancer cell line were chosen because previous studies 
had shown significant ADAM-10 expression in these cells (Williams, 2013). The 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
used in EC50 determination. This colourimetric assay is able to assess cell 
number based on the colour change of yellow tetrazolium salts (the MTT 
reagent) to form a reduced dark purple formazan crystal.  This assay measures 
cell metabolic activity, whereby a yellow to purple colour change is catalyzed by 
mitochondrial dehydrogenase in living cells, thus providing an indication of living 
cell numbers (Berridge and Tan, 1993).  
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EC50 data were obtained for GI254023X (Tocris Biosciences), and compared to 
the UCT generated SN-254, and SN-311. Hill plots used to determine the EC50 
values for GI254023X, SN-254 and SN-311 are shown in figure 3.3. The EC50 
values are summarized in Tables 3.2, 3.3, 3.4 and shows EC50 values within 
similar range for all three compounds in HeLa and WHCO5 cells. Interestingly all 
three small molecules produced EC50 values 3 – 4 fold times higher in the non-
cancer WI38 and FG0 cells compared to the cancer cells (Tables 3.2; 3.3 and 
3.4). These results show that SN-254 and SN-311 have EC50 in a similar range to 
that of the commercially available GI254023X, and that HeLa and WHCO5 
cancer cells are therefore sensitive to treatment with these molecules. 
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Figure 3.3: Hill plots for EC50 determination in (A) FG0 and (B) WI38 normal 
cell lines; (C) HeLa; and (D) WHCO5 with varying concentrations of (i.) SN-
254, (ii.) SN-311 and (iii.) GI254023X drugs respectively. All experiments were 
performed in triplicate and repeated three independent times. Results are the 
mean ± SEM. 
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Table 3.2: Small molecule SN-254 EC50 value in a panel of cell lines. 
 
 
Table 3.3: Small molecule SN-311 EC50 value in a panel of cell lines. 
 
Table 3.4: Small molecule GI254023X EC50 value in a panel of cell lines. 
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3.2.2 The effect of small molecules GI254023X, SN-311 and SN-254 on 
ADAM-10 activity – Human CX3CL1 fractalkine immunoassay 
 
The human fractalkine chemokine CX3CL1 exists both as a membrane bound 
protein, aiding in enhancing cell-cell adhesion as well as a soluble form, inducing 
chemotaxis (Hundhausen, et al., 2003). ADAM-10 has been described as a 
candidate protease for CX3CL1 cleavage. Previous studies showed that 
GI254023X significantly inhibited CX3CL1 cleavage by preferentially blocking 
ADAM-10 (Hundhausen, et al., 2003). To assess whether treating cancer cells 
with SN-254 and SN-311, newly synthesized precursor derivatives of GI254023X 
would be able to target the ADAM-10, and therefore affect its function, a 
functional assay based on detecting levels of cleaved, solubilized CX3CL1 was 
performed. This immunoassay allowed us to assess whether the newly 
synthesized derivatives inactivated ADAM-10. 
 
HeLa and WHCO5 were treated with GI254023X (as a positive control), SN-254 
and SN-311 respectively. Our results show a significant reduction in CX3CL1 
cleavage in both HeLa and WHCO5 cell lines treated with GI254023X (Figure 
3.4A and B). Our results also showed a decrease in cleaved CX3CL1 with SN-
254, SN-311 treatment in HeLa and WHCO5 respectively, (Figure 3.4A and B).  
These results suggest that the SN-254 and SN-311 have inhibitory effects in 
ADAM-10 activity similar to that of GI2540234X. 
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A. HeLa 
 
B. WHCO5 
 
Figure 3.4: Effect of test compounds on ADAM-10 activity: Human CX3CL1 
Fractalkine immunoassay. HeLa cervical cancer cell line (A) and WHCO5 
oesophageal cancer cell line (B) were treated with the calculated EC50; 2 X EC50; 
and a vector control (DMSO equivalent to EC50  concentration of the compound 
under investigation applied) of SN-254; SN-311 and GI254023X respectively. 
Cell lysate and media of each treatment condition was collected and plated into a 
pre-coated CX3CL1 ELISA plate. Results are the mean ± SEM of experiments 
performed in triplicate. The set of results show a decrease in cleaved CX3CL1 
post SN-254, SN-311 and GI254023X treatment in HeLa and WHCO5 
respectively. *p<0.05; **p<0.001. 
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3.2.3 Characterisation of the effect of GI254023X, SN-311 and SN-254 on 
the growth and proliferation of cancer cells 
 
3.2.3.1 Anchorage dependent proliferation 
 
Having established that GI254023X, SN-254 and SN-311, behave in a 
comparable manner in terms of IC50 and ADAM-10 inhibitory activity, further 
assays were performed to characterize its effect on cancer cell proliferation.  
 
HeLa and WHCO5 cells were treated with the EC50 and, 2X EC50 concentration 
of each of the small molecules, as well as the equivalent amount of DMSO to that 
of the 2X EC50 concentration, as a control. Cellular proliferation was monitored 
over a five-day period by the MTT assay. Results showed that GI254023X and 
SN-311 in HeLa caused a significant inhibition in proliferation from as early as 48 
hours after both EC50 and 2X EC50 treatment (Figure 3.5A and B). A less 
pronounced effect was observed with SN-254 (Figure 3.5C).  
 
Similar results were obtained with WHCO5 cells showing significant inhibitory 
effect with all three small molecules (Figure 3.6A-C). From this data, it can be 
deduced that GI254023X, SN-311 and SN-254, produced a significant inhibitory 
effect on the proliferation of both HeLa and WHCO5 cell lines respectively.  
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Figure 3.5: Proliferation assay, treating HeLa cervical cancer cell line with 
the EC50; 2 X EC50; Control (DMSO equivalent to 2X EC50 concentration of 
compound) of (A) GI254023X; (B) SN-311 and (C) SN-254 respectively. 
Cellular proliferation was monitored over a 5-day period. Results are the mean ± 
SEM of experiments performed in quadruplicate (*p<0.05). The results show that 
GI254023X and SN-311 had a significant inhibitory effect.  
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Figure 3.6: Proliferation assay, treating WHCO5 oesophageal cancer cell 
line with the IC50; 2 X IC50; Control (DMSO equivalent to 2X IC50 
concentration of compound) of (A.) GI254023X; (B.) SN-311 and (C.) SN-254 
respectively. Cellular proliferation was monitored over a 5-day period (*p<0.05). 
Results are the mean ± SEM of experiments performed in quadruplicate. The 
results show that GI254023X, SN-311 and SN254 had a significant inhibitory 
effect on the proliferation of WHCO5 oesophageal cancer cells.  
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3.2.3.2 The effect of GI24023X, SN254 and SN-311 on the clonogenic 
potential in cancer cells 
 
Clonogenic colony formation assay is described as an in vitro cell survival assay, 
This assay monitors the ability of a single cell to grow into a colony of at least 50 
cells (Franken, et al., 2006). The clonogenic assay is a widely used assay of 
tumorigenicity, and in this context, this assay was used to test the effect of 
certain agents on clonogenicity, a widely used marker of tumorigenicity  
 
Both HeLa and WHCO5 cancer cell lines were plated at 100 cells per 6-well 
plate, and treated 24 hours later with EC50 value, 2X EC50 value of each of the 
small molecules. The treated cells were left to grow for a period of 9 days. 
Thereafter, cells were stained with 0.5% crystal violet staining solution, and cell 
colonies formed were quantified under the stereomicroscope. Photographs were 
taken of each well, and colonies were quantified using the ColonyArea ImageJ 
Plugin, as described by Guzman and colleagues (2014). Plating efficiency and 
survival fraction was calculated (see methods). 
 
The result obtained showed a decrease in HeLa colonies with a concentration-
dependent increase in GI254023X (Figure 3.7A). The survival fraction 
percentage (%)for HeLa treated with GI254023X over 9 days is shown 
graphically, and shows a decrease in cell survival with increasing drug 
concentration (Figure 3.7).  
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Figure 3.7: Clonogenic colony formation assay in HeLa, treating HeLa 
cervical cancer cell line with the EC50; 2 X EC50; and DMSO equivalent to 
2X EC50 concentration of compound under investigation applied of (A) 
GI254023X; (B) SN-311 and (C) SN-254 respectively. Colony formation assay 
was monitored over a 9-day period. Results are the mean ± SEM of experiments 
performed in quadruplicate. The results show that GI254023X, SN-311 and 
SN254 had a significant inhibitory effect on the survival fraction and cellular 
survival of HeLa cells. Tabulated figures represents Survival Fraction % (SF%). 
SF% = (Plating efficiency of treated sample/ Plating efficiency of control) X 100.  
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Figure 3.8: Clonogenic colony formation assay in WHCO5, treating WHCO5 
oesophageal cancer cell line with the EC50; 2 X EC50; and DMSO 
equivalent to 2X EC50 concentration of compound under investigation 
applied of (A) GI254023X; (B) SN-311 and (C) SN-254 respectively. Colony 
formation assay was monitored over a 9-day period. Results are the mean ± 
SEM of experiments performed in quadruplicate. The results show that 
GI254023X, SN-311 and SN254 had a significant inhibitory effect on the survival 
fraction and cellular survival of WHCO5 cells. Tabulated figures represents 
Survival Fraction % (SF%). SF% = (Plating efficiency of treated sample/ Plating 
efficiency of control) X 100.  	 72	
 
 
Figure 3.8: Clonogenic colony formation assay in WHCO5, treating 
WHCO5 oesophageal cancer cell line with the IC50; 2 X IC50; and DMSO 
equivalent to 2X IC50 concentration of compound under investigation 
applied of (A.) GI254023X; (B.) SN-311 and (C.) SN-254 respectively. 
Colony formation assay was monitored over a 9-day period. Results are the 
mean ± SEM of experiments performed in quadruplicate. The results show 
that GI254023X, SN-311 and SN254 had a significant inhibitory effect on the 
survival fraction nd cellular survival of WHCO5 c lls. . Tabulated figures 
represents Survival Fraction % (SF%). SF% = (Plating fficiency of treated 
sample/ Plating efficiency of control) X 100.   
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The survival fraction percentage (%) calculated for HeLa treated with GI254023X 
over 9 days, showed, a decrease in colonies formed with an increase in 
treatment concentrations, reaching a value of 5.78% with 2X EC50 treatment 
concentration (Figure 3.7A). In SN-311 treated HeLa wells, a 32.5% and 62.4% 
decrease for EC50 and 2X EC50 respectively was noted in colonies when 
compared to the control wells, (Figure 3.7B). SN-254 treatment too showed a 
decrease in colonies compared to untreated cells (Figure 3.7C). While SN-254 
inhibited colony formation, it was not as effective an inhibitor as GI254023X and 
SN-311. SN-254 had reduced to 73.02% in EC50 concentration treatment, and 
48.02% in 2X EC50 concentration treatment (Figure 3.7C). These results are in 
line with what was observed in the proliferation assays.  
 
Similar results were obtained for WHCO5 cells, which showed that GI254023X 
and SN-311 inhibited WHCO5 colony formation to a greater extent than that of 
SN-254 (Figure 3.8A-C).  
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3.2.4 Cell death associated with GI254023X, SN-311 and SN-254 targeting 
ADAM-10 activity 
3.2.4.1 Effect of GI254023X, SN-311 and SN-254 on mode of cell death 
Having shown that GI254023X, SN-311 and SN-254 compounds resulted in the 
inhibition of HeLa and WHCO5 cell proliferation and growth, we next set out to 
investigate whether this inhibition associates with cell death via apoptosis. 
Apoptosis, described as a type 1 method of programmed cell death, regulates 
cellular self-destruction in response to a variety of stimuli (Portt, et al., 2011; Man 
and Kanneganti, 2016). Known too as a non- inflammatory form of programmed 
cell death, apoptosis is mediated by a family of proteases, called Cysteinyl 
aspartate-specific proteinases, or Caspases (Elmore, 2007; Man and 
Kanneganti, 2016). Thus, once Caspases are proteolytically activated, they 
generally activate a cascade of events that result in cell death through targeted 
cleavage of specific substrates (Elmore, 2007). Morphologically, cells undergoing 
apoptosis appear to undergo cell shrinkage or pynknosis, membrane blebbing as 
well as DNA fragmentation (Elmore, 2007; Man and Kanneganti, 2016).  
 
In this study, a commercially available Caspase 3/ 7 activity assay kit (Promega), 
was used to assess the levels of caspase – 3 and 7 enzyme activity, using a 
luminogenic tetrapeptide substrate. The level of luminescence detected is directly 
proportional to that of substrate cleavage by the Caspase- 3 and 7 enzymes, 
thus reflecting a level of apoptotic activity.  
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Caspase 3/7 activity assay results obtained in HeLa showed a significant 
increase in response to GI254023X and SN-311 treatment at both IC50 and 2X 
IC50 (Figure 3.9A and 3.9B). A significant increase in levels of caspase 3/7 
activities was only observed at the 2X IC50 treatment  with SN-254 treatment in 
HeLa(Figure 3.9C). 
 
Significant increase in caspase 3/7 activity was detected across all three 
compound treatments, GI254023X, SN-311 and SN-254 in WHCO5 oesophageal 
cancer cell line for both IC50 and 2X IC50 treatment conditions respectively (Figure 
3.10A – C). 
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Figure 3.9: The effect of GI254023X, SN-311 and SN-254 on induction of 
apoptosis in HeLa cells. HeLa cells were treated with 1X EC50; 2 X EC50; and 
DMSO only equivalent to 2XEC50 concentration of (A) GI254023X; (B) SN-311 
and (C) SN-254 respectively. The data above shows an increase in caspase 3/ 7 
activation with an increase in selected drug treatments. (*p.<0.05).  
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Figure 3.10: The effect of GI254023X, SN-311 and SN-254 on induction of 
apoptosis in WHCO5 cells. WHCO5 cells were treated with 1X EC50; 2 X EC50; 
and DMSO only equivalent to 2XEC50 concentration of (A) GI254023X; (B) SN-
311 and (C) SN-254 respectively. The data above shows an increase in caspase 
3/ 7 activation with an increase in selected drug treatments. (*p.<0.05).  
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3.2.4.2 The effect of GI254023X, SN-311 and SN-254 on Poly(ADP-Ribose) 
Polymerase-1 activation 
 
We next determined the extent of PARP cleavage as an alternate measure of 
apoptosis. PARP is a known substrate of activated caspase (Bock and Chang, 
2016; Kotsopoulos, 2016). Referred to also as ADP-ribosyltransferases (ART), 
humans express 17 such enzymes, which aid in altering targeted proteins by the 
unique modification of ADP-ribose attachment (Bock and Chang, 2016; Hottiger, 
et al., 2010; Kotsopoulos, 2016). PARP is involved in a range of cellular functions 
which include transcription regulation, cell division and mRNA stability (Bock and 
Chang, 2016).  
 
Better-understood and studied roles of PARP involve regulating cellular 
responses to stresses, which are induced by DNA damage response (DDR), 
unfolded protein response (UPR), and cytoplasmic stress response (Bock and 
Chang, 2016). Damage of DNA activates PARP-1and PARP-2 enzymes, which 
both assist in base excision repair (BER) pathway activities. These enzymes 
create an ADP-ribose homopolymer, ‘flagging’ the damaged area (Kotsopoulos, 
2016; Robert et al., 2013). This action driven by PARP induces histone release, 
loosening chromatin at the affected site, allowing for recruitment of additional 
mechanisms to repair and restore the DNA (Kotsopoulos, 2016; Robert et al., 
2013).  
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A PARP cleavage assay was performed by Western blot analysis. In response to 
activated caspase activity, PARP is cleaved from a 116kDa form to a 89kDa 
protein size (Kauffman, et al., 1993). PARP cleavage was analysed in HeLa and 
WHCO5 cell lines 48 hours after treatment with 1X IC50 and 2X IC50 
concentration values of GI254023X, SN-311 and SN-254, respectively. After the 
48-hour treatment interval, both floating cells and attached cells were collected 
and lysed with RIPA buffer (see Appendix I Solutions). The harvested cell lysates 
of HeLa and WHCO5 were subjected to Western Blot analysis with an α-PARP 
antibody.  
 
Both HeLa and WHCO5 cells showed PARP cleavage with EC50 and 2X EC50 
concentrations of GI254023X, SN-311 and SN-254 respectively (Figures 3.11 A 
and B). These results further confirm, that GI254023X, SN-311 and SN-254 
treatment of HeLa and WHCO5 cells results in cell death via apoptosis. 
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Figure 3.11: Poly (ADP-Ribose) Polymerase (PARP) cleavage detection in 
(A.) HeLa, and (B.) WHCO5. Uncleaved (precursor/ full length) PARP-1 
(116kDa) and cleaved PARP-1 (89kDa) was detected in HeLa and WHCO5 cell 
lines post treatment with the indicated concentration of 1X EC50 and 2 X EC50 
varying concentrations of (i) GI254023X, (ii) SN-311 and (iii) SN-254. DMSO 
only treatment served as the control variable for each small molecule treatment. 
The data shows that, when compared to the control band– both concentrations of 
each small molecule inhibitor induced significant PARP cleavage. GAPDH was 
used as a control for protein loading.  
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3.3 Discussion 
 
In this study we investigated the potential of ADAM-10 as a therapeutic target in 
oesophageal cancer and cervical cancer, using a known small molecule inhibitor 
of ADAM-10, GI254023X, as well as the novel small molecules SN-254 and SN-
311. This study was carried out given the evidence in the literature that tumour 
tissue express higher levels of ADAM-10, as well as previous data generated in 
our laboratory confirming this elevated ADAM-10 expression in cancer cells 
(Arribas et al., 2006; Camodeca, et al., 2016; Saftig and Reiss, 2011; Zhang, et 
al., 2014; Zhao, et al., 2014; Ward, 2011; Williams, 2013).  
 
Previous reports (Hundhausen, et al., 2003; Ludwig, et al., 2005; Moss, et al., 
2007; Hoettecke, et al., 2010) had cited GI254023X IC50 value at a range 
between 5 and 10 µM. Using this concentration of GI254023X in our laboratory 
had proven ineffective to induce cell death (Williams, 2013 unpublished data). 
Recently, a research group investigating ADAM-10 involvement in cell junction 
assembly during early porcine embryo development had established an IC50 
concentration of GI254023X to be 100 µM (Kwon, et al., 2016). Camodeca and 
colleagues (2016) using Hodgkin's lymphoma cells established an IC50 of 
GI254023X to be 27 µM.  Comparisons of EC50 values in our laboratory of the 
three compounds had shown the EC50 value obtained in GI254023X in HeLa is 
80 µM, and WHCO5 is 111 µM. The newly synthesized precursor compounds 
SN-254, and SN-311 generated EC50 values within a similar range to that for 
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GI254023X, as the 95% Confidence Interval range of all three compounds 
overlapped.  
  
Having determined the concentration where the novel compounds block cell 
growth, we next set out to assess whether SN-311 and SN-254 would be able to 
target and subsequently inhibit a known ADAM-10 function. As such, the human 
fractalkine CX3CL1 immunoassay was performed. ADAM-10 is described 
throughout literature as a candidate for constitutive cleavage of CX3CL1, thus 
solubilizing this transmembrane protein via shedding activity (Hundhausen, et al., 
2003). Prior research has also shown that GI254023X is able to reduce 
significantly the cleavage of human fractalkine by preferentially blocking ADAM-
10 activity (Hundhausen, et al., 2003). To assess whether treating cancer cells 
with SN-254 and SN-311, is able to target ADAM-10 activity, a functional assay 
based on detecting levels of cleaved, solubilized CX3CL1 was performed. In 
accordance with literature, the levels of CX3CL1 cleaved to its shed soluble form 
in both HeLa and WHCO5 cell lines treated with GI254023X decreased 
significantly. Furthermore, we were able to show that both SN-311 and SN-254 
were able to induce a decrease in cleaved soluble CX3CL1 levels, suggesting 
that the newly derived precursor small molecule compounds are able to target 
ADAM-10 (like GI254023X) by inactivating its shedding function. The ability of 
SN-311 and SN-254 to target and inhibit an ADAM-10 functional activity, similar 
to GI254023X, could stem from the structural similarity that these three 
compounds share.  
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After establishing that SN-311 and SN-254 were able to induce a comparable 
inhibitory effect on cancer cell growth, and, moreover, that the two new 
compounds were able to target and inhibit an ADAM-10 functional activity like 
that of GI254023X, by inactivating its’ shedding function, further assays were 
performed to characterize its effect on cancer cell proliferation. Results obtained 
post treatment with GI254023X, SN-311 and SN-254 in both HeLa and WHCO5 
cells had showed a significant inhibition in proliferation. The result obtained in 
GI254023X treatments was in accordance with literature, citing it as a small 
molecule able to decrease proliferation in a range of cancers, including breast, 
hepatocellular carcinoma and tongue squamous cell carcinoma (Duffy, et al., 
2011; Fu, et al., 2014; Zhang, et al., 2013; Shao, et al., 2015).  
 
Literature cites the ability of different ADAMs family members able to perform 
compensatory roles for each other, which, may explain why 100% cell death was 
not achieved. ADAM-10 is described as structurally and functionally related to 
ADAM-17, and both are shown to be leading proteases in trans-membrane 
protein ectodomains (Mullooly, et al., 2016; Bzowska, et al., 2009). Research has 
further linked ADAM-10 and ADAM-17 as able to compensate functionally in the 
absence of the other (Bzowska, et al., 2009). ADAM-10 and ADAM-17 are known 
to activate epidermal-like growth factor receptor (EGFR), which contributes to 
cancer proliferation (Mullooly, et al., 2016, Sahin, et al., 2004). It is, therefore 
possible that in the presence of an inhibited ADAM-10 in HeLa and WHCO5 cells 
induced by a small molecule, GI254023X, which is known to possess a 100 fold 
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biological affinity to ADAM-10 over ADAM-17, ADAM-17 would functionally 
compensate for the inhibited ADAM-10 activity (Mullooly, et al., 2016).  
 
Having shown that treatment with GI254023X, SN-311 and SN-254 compounds 
resulted in the suppression of HeLa and WHCO5 cell proliferation and growth, 
we investigated whether this inhibition was due to cell death induced by 
apoptosis. A quantitative caspase 3/7 assay and PARP cleavage assay was 
performed. Our results obtained in HeLa and WHCO5 cancer cell lines had 
shown significant increases in caspase 3/7 activity levels and PARP cleavage in 
treatments with GI254023X and SN-311. 
 
Furthermore, the results obtained of cell death induced by GI254023X, SN-311 
and SN-254 treatment in HeLa and WHCO5 cells, suggest that apoptosis was a 
mechanism involved. Our findings for GI254023X correspond with literature, 
where GI254023X was shown to not only block cell proliferation, but also induced 
apoptosis within acute T-lymphoblastic leukaemia Jurkat cells (Mullooly, et al., 
2016; Ma, et al., 2015). 
 
In summary, the current study has established that the two newly derived 
precursor derivatives of GI254023X, namely SN-311 and SN-254 has a similar 
IC50 concentration range in the two cancer cell lines studied here, and that SN-
311 and SN-254 is able to inhibit ADAM-10 cellular functions (shedding of 
CX3CL1). Furthermore, the derivatives are able to inhibit cellular proliferation, 
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although producing a weaker effect to that of GI254023X. This study has also 
shown that SN-311 and SN-254, are able to induce cell death by activating 
caspase 3/7 activity and increasing cleavage of PARP.   
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Chapter 4: 
Investigating the effects of GI254023X, SN-311 and SN-254 on cancer 
biology and progression 
 
 
4.1 Introduction 
 
In the previous chapter, we reported that GI254023X and precursors SN-311 
and SN-254, were able to reduce cell proliferation of HeLa cervical and 
WHCO5 oesophageal cancer cell lines, as well as induce cell death via 
apoptosis. In this chapter we assess whether GI254023X, SN-311 and SN-
254 affect other cancer hallmarks such as migration, invasion, adhesion, and 
activation of epithelial transition markers in oesophageal and cervical cancer 
cells.   
 
Recently, GI254023X was shown to inhibit migration and invasion of breast 
cancer cell lines, as well as in cancer cell lines of the stomach, oral cavity and 
the ovary (Mullooly, et al., 2016; Mullooly, et al., 2015; Mochizuki and Okada, 
2007). Furthermore, GI254023X has also been reported to induce different 
effects on cancer biology i.e. inhibition of cell growth, proliferation, migration 
and invasion in different cell lines shown in in vitro studies (Mullooly, et al., 
2016). This suggests that the biological activities affected by ADAM-10 may 
well be cell-type specific, and probably largely dependent on the ectodomain 
substrates it acts on (Mullooly, et al., 2016). This was illustrated when 
GI254023X reduced pancreatic cancer cell line migration and invasion, but 
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failed to affect proliferation (Gaida, et al., 2010; Mullooly, et al., 2016); whilst 
in skin cancer cell lines and bladder cancer cell lines, this small molecule 
induced significant suppression of both cellular proliferation and migration 
(Lee, et al., 2010; Fu, et al., 2014). In addition, GI254023X has been shown to 
reduce the cleavage of E-cadherin, a biomarker of cell-cell communication 
and adhesion (Reiss, et al., 2005; Mullooly et al., 2016). 
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4.2 Results 
 
4.2.1 Effect of GI254023X, SN-254 and SN-311 on actin levels in cancer 
cells 
 
Since its discovery within non-muscular cells, the filamentous actin (F-actin) 
cytoskeletal network has been well studied and shown to be a critical role-
player in regulating numerous biophysical and biochemical signals to control a 
variety of cell processes, such as cellular adhesion, migration, invasion as 
well as proliferation (Byron and Frame, 2016; Stricker, Falzone, and Gardel, 
2010). ADAM-10 has been linked with the ectodomain cleavage of many 
adhesion related factors, impacting on cell-cell adhesiveness and tethering to 
the extracellular matrix (ECM), as well as ectodomain surface binding, and 
shedding receptor targets such as E-cadherin, and B-catenin translocation 
(Maretzky, et al., 2005). These factors can affect the overall size and shape of 
cells, the cytoskeletal arrangement as well as whether cells exhibit a more 
mesenchymal or epithelial phenotype (Byron and Frame, 2016; Stricker, 
Falzone, and Gardel, 2010).  
 
To investigate the effect of blocking ADAM-10 activity by GI254023X on the 
cytoskeletal arrangement, size and cell shape of HeLa and WHCO5 cells, an 
actin staining assay was performed using phalloidin. These cells were also 
treated with SN-311 and SN-254 to determine the effect of these agents on 
the parameters assessed. Phalloidin fluorescent stains for the polymeric 
filamentous –actin (F-actin). Briefly, HeLa and WHCO5 cell lines were 
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cultured on coverslips, and once the cells had settled, they were treated with 
1X EC50 and 2X EC50 of GI254023X, SN-254 and SN-311. 24 hours after 
treatment, the cells were fixed and stained for F-actin with phalloidin. 
Phalloidin staining revealed F-actin distribution shown in red, whilst Hoechst 
was used to stain for cellular nuclei (shown in blue). This was viewed by 
fluorescence microscopy.  
 
Our results in both HeLa and WHCO5 cells displayed a decrease in F-actin 
staining in response to treatment with increasing concentrations of the agents 
tested (Figure 4.1 and Figure 4.2). Results obtained showed a significant 
decrease in F-actin staining at both 1X EC50 and 2X EC50 for all of the 
compounds tested (bar graphs Figure 4.1 and Figure 4.2). With the exception 
of SN-254, where the effect of this compound on phalloidin staining in 
WHCO5 cells was not significant at 1X EC50.  
 
These results suggest that SN-311 and SN-254 is able to suppress F-actin 
forming, similar to that of GI254023X in both WHCO5 and HeLa cell lines 
(with the note that SN-254 was less active in WHCO5 cells).  
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Figure 4.1: Phalloidin staining revealed Filamentous (F) actin 
distribution (shown in red), and Hoechst was used to stain for cell nuclei 
(blue) in HeLa post treatment with (A) GI254023X, (B) SN-311 and (C) SN-
254 respectively. Results show a global decrease in F-actin expression 
levels in response to treatment with increasing concentrations of the indicated 
compounds (*p.<0.05; **p<0.01; ***p<0.001).  
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Figure 4.2: Phalloidin staining revealed Filamentous (F) actin 
distribution (shown in red), and Hoechst was used to stain for cell nuclei 
(blue) in WHCO5 post treatment with (A) GI254023X, (B) SN-311 and (C) 
SN-254 respectively. Results show a decrease in F-actin expression levels in 
response to treatment with increasing concentrations of the GI254023X and 
SN-311 compounds, however only a 2X EC50 treatment of SN-254 caused a 
significant decrease in F-actin expression (*p<0.05; **p<0.01). 
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4.2.2 Effects of ADAM10 inhibition on cancer cell adhesion 
 
The decrease in F-actin expression observed on treatment with GI254023X, 
SN-311 and SN-254 suggested that inhibiting ADAM-10 activity, may affect 
cell adhesion, migration, as well invasion properties since Filamentous (F) 
actin has been linked with multiple biophysical cellular processes, including 
cellular adhesion (Byron and Frame, 2016; Stricker, Falzone, and Gardel, 
2010). We consequently investigated the effects of GI254023X, SN-254 and 
SN-311 on cell adhesion in HeLa and WHCO5 cells.  
 
Previous work conducted in our laboratory using ADAM-10 shRNA treatment 
showed a significant increase in cell adhesion in both cervical and 
oesophageal cancer cell lines (Williams, 2013, unpublished thesis). In this 
study we wanted to assess whether GI254023X, a small molecule inhibitor of 
ADAM-10 has similar effects, and also assess the effects of the novel 
molecules, SN-311 and SN-254 To assess the effect of these small 
compounds on cell adhesion, two adhesion assays were performed: non-
coated and a fibronectin-coated adhesion assays. These two experimental 
conditions were used to analyse two types of adhesion, cell – cell adhesion 
modelled in the fibronectin assay, and cell-surface (ectodomain) adhesion 
modelled in the non-coated assay. Fibronectin is a widely distributed large 
extracecellular matrix (ECM) glycoprotein molecule implicated in several 
cellular adhesive functions, such as cell – to – cell attachment, cell –to – 
basement membrane attachment (Proctor, 1987; Wang, et al., 2016). 
Furthermore, as fibronectin is described too as a mechanoregulator of the 
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ECM, the use of a fibronectin coated adhesion assay has been reported to 
assess whether the ADAM-10 small molecule inhibitors have the ability to 
stop the remodelling of the tumour stroma microenvironment that facilitate 
cancer invasion and metastasis (Wang, et al., 2016).  
 
Briefly, both HeLa and WHCO5 cell lines were treated with: GI254023X, SN-
311 or SN-254 at EC50 and 2X EC50 concentrations. Thereafter, non-coated as 
well as fibronectin-coated adhesion assays were performed using 96-well 
tissue culture plates, as described in Materials and Methods.  
 
Results obtained from both the non-coated (Figure 4.3A) and fibronectin-
coated adhesion (Figure 4.3B) assay conditions showed a significant increase 
in cell adhesion in HeLa cells after treatment with GI254023X, SN-311, and 
SN-254. A similar increase was detected in the WHCO5 cell line, after 
treatment with all three of the small molecule inhibitors  (Figure 4.4). Our data 
therefore suggests that an inhibition of ADAM-10 activity with GI254023X, 
leads to an increase in HeLa and WHCO5 cellular adhesion. Furthermore, 
treatment with SN-311 and SN-254 in HeLa and WHCO5 showed a similar 
result. 
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Figure 4.3: The effect of GI254023X, SN-311 and SN-254 on HeLa cervical 
cancer cell line cellular adhesion – (A) non-coated and (B) fibronectin-
coated. GI254023X (4.3Ai & 4.3Bi), SN-311 (4.3Aii & 4.3Bii) and SN-254 
(4.3Aiii &4.3Biii) treatment caused an increase in HeLa cell adhesion. HeLa 
cell line was treated with EC50 and 2 X EC50 values of GI254023X, SN-311 
and SN-254; and DMSO equivalent to 2X EC50 concentration of the 
compound under investigation applied (serving as the control). Experiments 
were performed in quadruplicate and repeated at least three independent 
times. Results are presented as the mean ± standard error of mean (SEM). 
Data presented above was normalized to the experiment control. Adherent 
cells were expressed relative to total cell number, and the control variables 
were normalised to a value of 1.  (*p<0.05; **p<0.01). 
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Figure 4.4: The effect of GI254023X, SN-311 and SN-254 on WHCO5 
oesophageal cancer cell line cellular adhesion – (A) non-coated and (B) 
fibronectin-coated. GI254023X (4.4Ai & 4.4Bi), SN-311 (4.4Aii & 4.4Bii) and 
SN-254 (4.4Aiii &4.4Biii) treatment caused an increase in WHCO5 cell 
adhesion. WHCO5 cell line was treated with EC50 and 2 X EC50 values of 
GI254023X, SN-311 and SN-254; and DMSO equivalent to 2X EC50 
concentration of the compound under investigation applied (serving as the 
control). Experiments were performed in quadruplicate and repeated at least 
three independent times. Results are presented as the mean ± standard error 
of mean (SEM). Data presented above was normalized to the experiment 
control. Adherent cells were expressed relative to total cell number, and the 
control variables were normalised to a value of 1.  (*p<0.05; **p<0.01). 
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4.2.3 The effect of GI254023X, SN-311, and SN-254 on cancer cell 
migration 
 
Cell migration is described as a complex process that is required for 
physiological growth and development, as well as repair and regeneration of 
tissue (Arribas, Bech-Serra and Santiago-Josefat, 2006). Cell migration also 
plays a critical role in metastasis and invasion (Arribas, Bech-Serra and 
Santiago-Josefat, 2006; Clark and Vignjevic, 2015).  
 
A range of in vitro studies has identified several factors regulating cancer 
migration mode and dynamics. These factors include, single-cell migration, 
multicellular streaming as well as collective migration (Clark and Vignjevic, 
2015). Single cell migration is caused by a lack of cell-cell interaction during 
migration activity. When increased contractility, whilst under the intrinsic factor 
regulation of the Rho-pathway is favoured, an amoeboid-like motility is 
experienced (Clark and Vignjevic, 2015; Wolf, et al., 2003).  Other individually 
moving cells may present as a mesenchymal phenotype, characterised by 
their spindle shaped cell body and protrusions (Clark and Vignjevic, 2015). 
Multicellular streaming is seen in non-adherent cells able to migrate along a 
similar path (Friedl and Gilmour, 2009; Friedl and Alexander, 2011). Collective 
migration describes groups of cells retaining the cell-cell adhesion and moves 
either as a narrow strand or as irregular multiple sheets of mixed phenotype 
cells (Khalil and Friedl, 2010; Clark and Vignjevic, 2015).  
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Having established that treatment with GI254023X induced a decrease in F-
actin formation in HeLa and WHCO5 cancer cell lines, we next investigated 
whether this compound would inhibit migration. We also tested the effects of 
SN-311 and SN-254 in the assay. For this, we performed a Transwell 
migration assay. The principle behind this assay is based on two- medium 
containing chambers, separated by a permeable membrane (usually tissue-
culture treated microporous membrane) through which cells can transmigrate. 
Cells are plated in one chamber, and separated from the other chamber that 
contains a chemoattractant, that should trigger cell migration. In this 
experiment, HeLa and WHCO5 cells were plated and treated with the 
indicated concentrations of GI254023X, SN-311 and SN-254.  
 
24 hours later, treated cells were re-plated in triplicate into Transwell 8µM 
pore inserts containing 1% FCS media, allowing for vertical directed migration 
of the cells through the pores of the membrane into the lower chamber of the 
24-well plate containing a higher serum concentration medium (20% FCS), 
serving as a chemo-attractant. After 24 hours, cells that had migrated across 
to the underside of the membrane were fixed with methanol and stained with 
crystal violet. The total number of migrated cells was normalised for each 
condition to controls. 
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Figure 4.5: The effect of GI254023X, SN-311, and SN-254 on HeLa 
cervical cancer cell line migration. (A) Photographs of 8µM pore inserts 
after different treatment, taken with a phase contrast Zeiss microscope (X100 
magnification). (B) Quantified densitometric analysis of relative number of 
cells migrated through the insert per treatment condition. Experiments were 
performed in quadruplicate and repeated at least two times. Results are 
presented as the mean ± standard error of mean (SEM). Data presented was 
normalized to the experiment control. Adherent cells were expressed relative 
to total cell number, and the control variables where normalised to a value of 
1. * p<0.05; ** p<0.01. Size bar represents 50 µM. 
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Figure 4.6: The effect of GI254023X, SN-311, and SN-254 on WHCO5 
oesophageal cancer cell line migration. (A) Photographs of 8µM pore 
inserts after different treatment, taken with a phase contrast Zeiss microscope 
(X100 magnification). (B) Quantified densitometric analysis of relative number 
of cells migrated through the insert per treatment condition. Experiments were 
performed in quadruplicate and repeated at least two times. Results are 
presented as the mean ± standard error of mean (SEM). Data presented was 
normalized to the experiment control. Cells were expressed relative to total 
cell number, and the control variables where normalised to a value of 1. * 
p<0.05; ** p<0.01. Size bar represents 50 µM. 
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Our data clearly indicated a significant decrease in HeLa cell migration 
(Figure 4.5A and 4.5B) in response to treatment with GI254023X (50% 
decrease; p<0.05), SN-311 (25% decrease; p<0.05), and SN-254 (30% 
decrease; p<0.05) at the EC50 respectively. Similarly in WHCO5 cells, we 
observed a statistically significant (p<0.05) decrease in cell migration after 
treatment with GI254023X (40% decrease) and SN-311 (50% decrease) with 
the EC50 concentration (Figure 4.6A and B). However, SN-254 only caused a 
significant reduction (40%, p<0.05) in cell migration at 2X EC50 treatment 
(Figure 4.6B). These results suggests that inhibition of ADAM-10 activity in 
both HeLa and WHCO5 cells with the small molecule inhibitor GI254023X, is 
associated with a substantial reduction (50%; p<0.05) in cell migration. 
Treatment with SN-311 and SN-254 had a similar effect, although SN-254 
seemed less effective than SN-311 and GI254023X.  
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4.2.4 The effect of GI254023X, SN-311, and SN-254 on cancer cell 
invasion 
 
A hallmark of metastatic cells is its ability to both migrate and invade into 
other tissues, organs within the body (Friedl and Alexander, 2011), and 
although cancer is often described as a disease of uncontrolled cellular 
proliferation, at its most lethal form, it could be described as a disease of 
unregulated cellular invasion (Clark and Vignjevic, 2015). Since treatment of 
HeLa and WHCO5 cells with GI254023X, SN-311 and SN-254 resulted in 
significant inhibition of migration, we next investigated whether these 
compounds had any effect on the invasive properties in HeLa and WHCO5 
cells. 
 
HeLa and WHCO5 were cultured and pre-treated with GI254023X, SN-254 
and SN-311, after which they were re-plated into 1% FCS-containing media in 
a matrigel-coated chamber (Corning Matrigel Invasion Assay kit, USA). Cells 
invading through the matrigel layer towards the 20% FCS in the lower 
chamber were fixed and stained 24 hours later. Cell numbers were quantified 
and normalised to controls as described in Material and Methods.  
 
The results obtained showed a significant reduction in HeLa and WHCO5 
invasion when treated with GI254023X, SN-311 and SN-254 (Figure 4.7A – 
B). Treatment with GI254023X resulted in a 30% and 50% decrease in HeLa 
and WHCO5 cells invasion (p<0.05) at 1X EC50 respectively. A smaller 
reduction (20 – 30%; p<0.05) in invasion was observed with treatment of 
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HeLa and WHCO5 cells with SN-311 at 1X EC50 respectively.  SN-254 
caused a significant (40%; p<0.05) decrease in HeLa cell invasion 1X EC50 
treatment. Furthermore, SN-254 only caused a significant reduction (40%; 
p<0.05) in WHCO5 cell invasion at 2X EC50 treatment (Figure 4.7B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 100	
 
Figure 4.7: The effect of GI254023X, SN-311 and SN-254 on (A) HeLa, and 
(B) WHCO5 cancer cell invasion. HeLa and WHCO5 cancer cell lines were 
treated with EC50 and 2X EC50 equivalents of SN254, SN-311 and 
GI254023X; (DMSO only served as the control variable). Experiments were 
performed in triplicate and repeated at least two times. Results are presented 
as the mean ± standard error of mean (SEM). Data presented was normalized 
to the experiment control. Migrated cells were expressed relative to total cell 
number, and the control variables were normalised to a value of 1. * p<0.05; 
** p<0.01.  
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4.2.5 The effect of GI254023X, SN-311, and SN-254 on cancer cell 
epithelial and mesenchymal phenotype markers: E-Cadherin, B-
Catenin and Vimentin  
 
Our data has shown significant increases in cell adhesion (non-coated and 
fibronectin-coated plastic surfaces) accompanied with a reduction in both 
migration and invasion activity, a decrease cellular proliferation as well as a 
decrease in F-actin expression levels in the presence of GI254023X, SN-311 
and SN-254.  
 
As described in chapter 1, tumour progression frequently involves an EMT 
with cells displaying altered morphology (Sethi, et al., 2011), as well as a loss 
of epithelial cellular adhesive ligand marker such as E-Cadherin, B-Catenin 
(Sethi, et al., 2011). This is accompanied by an increase in expression and 
acquisition of mesenchymal markers like vimentin (Sethi, et al., 2011; 
Christiansen and Rajasekaran, 2006). EMT progression can be monitored by 
the detection of biomarkers including epithelial adhesion based markers, E-
Cadherin and B-Catenin, or mesenchymal derived markers such as vimentin 
(Sethi, et al., 2011).  
 
Literature has identified ADAM-10 as a protein enzyme responsible for E-
cadherin ectodomain shedding (Maretzky, et al., 2005), hence ADAM-10 may 
be a useful target to reduce invasion and metastasis of cancers (Maretzky, et 
al., 2005).  
 
	 102	
To assess whether inhibition of ADAM-10 could alter the epithelial / 
mesenchymal phenotypic balance in HeLa and WHCO5 cells, the expression 
levels of E-Cadherin, B-Catenin and Vimentin was detected by western blot 
analysis.  Our results in HeLa cells showed an increase in E-Cadherin and B-
Catenin levels after treatment with GI254023X, and SN-311 (Figure 4.8A, and 
4.8B), whereas the effect of SN-254 on E-Cadherin and B-Catenin levels was 
barely noticeable (Figure 4.8C). Conversely, a decrease in Vimentin levels 
was observed after GI254023X and SN-311 (Figure 4.8A and B) treatment. 
No change in Vimentin levels was observed on SN-254 treatment (Figure 
4.8C).  
 
Similar results were obtained in WHCO5 cells. A substantial increase in E-
Cadherin (observed as a double band in WHCO5 cells, this double band was 
noted in two other oesophageal cancer cell lines test in our laboratory, namely 
KYSE30 and WHCO6) and B-Catenin levels observed in WHCO5 cells 
treated with GI254023X and SN-311, whereas SN-254 increased E-Cadherin 
levels substantially, but only caused a small increase in B-Catenin levels 
(Figure 4.9A-C). A decrease in Vimentin levels was noted for each of the 
compounds in WHCO5 (Figure 4.9A-C). Together these results show that 
GI254023X, SN-311 and SN-254 causes an elevation in epithelial phenotype 
markers such as E-Cadherin and B-Catenin expression levels, whilst 
decreasing the levels of a mesenchymal phenotype marker, Vimentin 
suggesting that these small molecules could alter epithelial to mesenchymal 
cell phenotype transition in HeLa and WHCO5 cells. 
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Figure 4.8: The effect of (A) GI254023X, (B) SN-311 and (C) SN-254 on 
HeLa cervical cancer cell epithelial and mesenchymal phenotype 
markers. E-Cadherin (120kDa), B-Catenin (92kDa) and Vimentin (57kDa) 
was detected in HeLa cells. GAPDH was used as a control for protein loading. 
Experiments were performed in quadruplicate and repeated at least three 
times. 	
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Figure 4.9: The effect of (A) GI254023X, (B) SN-311 and (C) SN-254 on 
WHCO5 oesophageal cancer cell epithelial and mesenchymal phenotype 
markers. E-Cadherin (120kDa), B-Catenin (92kDa) and Vimentin (57kDa) 
was detected in WHCO5 cells. GAPDH was used as a control for protein 
loading. Experiments were performed in quadruplicate and repeated at least 
three times. 
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4.2.6 The effect of GI254023X, SN-311, and SN-254 on VEGF expression 
levels  
 
Having detected a decrease in migration, invasion and cellular proliferation, 
accompanied with changes in the levels of markers that associate with 
epithelial and mesenchymal transition in the presence of GI254023X, SN-311 
and SN-254, we next set out to investigate whether these compounds affect 
angiogenic growth factors, which regulate the process of angiogenesis. 
Angiogenic factors, such as the vascular endothelial growth factor (VEGF), is 
instrumental in maintaining the vasculature status as well as further 
enhancing growth and development of tissues requiring new blood vessels 
(Verheul and Pinedo, 2000). A potent specific angiogenic factor, many studies 
have shown that VEGF induces angiogenesis, and contributes significantly to 
the regulation of vasculogenesis (Neufeld, et al., 1999; Donners, et al., 2010; 
Li et al., 2015).   
 
Previous studies have shown that inhibiting ADAM-10 via siRNA resulted in 
the decrease in expression and secretion of vascular endothelial growth factor 
A (VEGF-A) (Li, et al., 2015; Isozaki, et al., 2013; Dreymeuller, et al., 2012). 
Based on this published work, we investigated whether GI254023X, SN-311 
and SN-254 could similarly affect VEGF levels in oesophageal and cervical 
cancer cells.  
 
The results obtained showed a reduction in VEGF levels when ADAM-10 was 
inhibited with GI254023X in HeLa and WHCO5 cells (Figure 4.10A and 
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4.11A). A similar effect was detected after HeLa and WHCO5 cells were 
treated with SN-311 (Figure 4.10B and 4.11B). Furthermore, treatment of 
HeLa and WHCO5 with SN-254, induced a decrease in VEGF expression, 
albeit not as strongly as with GI254023X and SN-311 (Figure 4.10C; Figure 
4.11C). It must be highlighted that detecting for VEGF expression in SN-254 
treated HeLa cells had consistently produced faint VEGF bands (Figure 
4.10C). SN-254 treated WHCO5 cells, though produced a reduction in VEGF 
expression at EC50 concentration, no further decreases in expression was 
detected at 2X EC50 treatment (Figure 4.11C), which could be attributed to 
difficulty experienced in western blotting transfer step.  
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Figure 4.10: The effect of (A) GI254023X, (B) SN-311 and (C) SN-254 on 
VEGF expression in HeLa cervical cancer cells. VEGF (21kDa) was 
detected in HeLa cancer cells. GAPDH was used as a control for protein 
loading. Quantitation of VEGF expression (histogram below each compound 
treatment) relative to GAPDH determined by densitometry of western blot 
band intensity using ImageJ software. Results are representative of 
experiments performed at least two independent times.  
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Figure 4.11: The effect of (A) GI254023X, (B) SN-311 and (C) SN-254 on 
VEGF expression in WHCO5 oesophageal cancer cells. VEGF (21kDa) 
was detected in WHCO5 cancer cells. GAPDH was used as a control for 
protein loading. Quantitation of VEGF expression (histogram below each 
compound treatment) relative to GAPDH determined by densitometry of 
western blot band intensity using ImageJ software. Results are representative 
of experiments performed at least two independent times. 
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4.3 Discussion 
 
In this study, we reported that treatment with GI254023X, SN-254 and SN-311 
in HeLa, and WHCO5 cell lines, induced an inhibitory effect on F-actin levels 
as well as on cell migration and invasive abilities. This was accompanied with 
an increase in both cell to cell and cell to surface adhesion properties. We 
also reported an increase in epithelial phenotypic markers, E-Cadherin and B-
Catenin, with a simultaneous decrease in mesenchymal cell marker, Vimentin, 
and suppression of vascular endothelial growth factor (VEGF) after treatment 
with GI254023X, SN-254 and SN-311.    
 
The data generated suggest that the inhibition of ADAM-10 with treatment of 
GI254023X in HeLa and WHCO5, leads to the observed increase of markers 
associated with the epithelial phenotype (increase in E-Cadherin, and B-
Catenin), coupled with a decrease in expression of markers associated with 
mesenchymal phenotype (decrease in Vimentin). A similar trend was detect 
with treatment with SN-311, and to a lesser extent, SN-254. These results 
collectively show that these compounds are able to cause an elevation in 
markers associated with the epithelial phenotype, whilst simultaneously 
decreasing mesenchymal phenotype markers. It suggests that these small 
molecules are able to suppress epithelial to mesenchymal transition.  
 
A recent study silencing ADAM-10 expression in gastric and leukaemia cells 
induced an up-regulation of the epithelial marker, E-Cadherin, and a 
suppression of the mesenchymal marker, Vimentin (You, et al., 2015). The 
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results of You and colleagues (2015) therefore suggest that targeting ADAM-
10 expression can effect cell phenotype. Our study similarly showed that 
inhibiting ADAM-10 activity with small molecules resulted in an increase in E-
Cadherin and a decrease in Vimentin. High ADAM-10 has been reported to 
associate with transformation of cell morphology into structures that increase 
cellular motility, as well as a loss of epithelial cellular adhesive ligand marker 
such as E-Cadherin, B-Catenin, accompanied by the increase in expression 
and acquisition of mesenchymal markers like Vimentin (Sethi, et al., 2011; 
Christiansen and Rajasekaran, 2006). Such changes noted within invading 
cells are characteristic of epithelial to mesenchymal transition (EMT). 
Furthermore, ADAM-10 has been identified to be responsible for activating E-
Cadherin (Maretzky, et al., 2005; Zhang, et al., 2014; Li, et al., 2016), as well 
as contributing to B-Catenin translocation (Maretzky, et al., 2005). 
 
ADAM-10 up-regulation has been associated with the growth and metastasis 
of many cancers, these include non-small lung cancer, oral cavity, stomach as 
well as ovarian cancers (Mullooly, et al., 2016; Mullooly, et al., 2015; 
Mochizuki and Okada, 2007). Structural features expressed within metastatic 
cells compared to normal cells include cytoskeletal organization 
rearrangement, unregulated growth, migration, and invasion. To assess for 
possible cytoskeletal changes in HeLa and WHCO5 cells, post ADAM-10 
suppression with small molecule inhibitor GI254023X treatment, F-actin 
cytoskeletal protein suppression in expression levels were detected via a 
phalloidin staining. The filamentous actin (F-actin) cytoskeletal network was 
been well studied and shown to be a critical role- player in regulating 
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numerous biophysical and biochemical signals to control and process a 
variety of cell behaviours, such as cellular adhesion, migration, invasion as 
well as proliferation (Byron and Frame, 2016; Stricker, Falzone, and Gardel, 
2010).  
 
The association of ADAM-10 with the ectodomain cleavage of many adhesion 
related factors linked to cell-cell adhesiveness and the extracellular matrix 
(ECM) as well as cell ectodomain surface binding and shedding receptor 
targets such as E-Cadherin, and B-Catenin translocation has been well 
researched (Maretzky, et al., 2005). Our results also indicated a similar trend 
in suppression of phalloidin staining with a corresponding increase in 
treatment by the novel compounds SN-311 and SN-254.  
 
Filamentous (F) actin is linked with multiple biophysical cellular processes 
such as cellular adhesion (Byron and Frame, 2016; Stricker, Falzone, and 
Gardel, 2010), Previous work conducted in our laboratory had shown 
significant increases in cell adhesion in HeLa and WHCO5 when ADAM-10 
was inhibited using shRNA ADAM-10 (Williams, 2013, unpublished data). Our 
data showing significant increases in cell adhesion after treatment with 
GI254023X is in accordance with previous reported studies (Maretzky, et al., 
2005). Our results also show that treatment with SN-311 and SN-254 can 
similarly increase cellular adhesion, suggesting that these compounds are 
able to perform functionally similar to GI254023X. This observation is 
consistent with the results obtained regarding the increase in E-Cadherin and 
B-Catenin expression. 
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Our results obtained in assessing the effect of GI254023X, SN-311 and SN-
254 on cancer cell migration and adhesion, showed significant reduction in 
migratory and invasive HeLa and WHCO5 cancer cells, suggesting a 
functional role for ADAM-10 in cervical and oesophageal cancer cell migration 
and invasion. Our results align with other studies, which has shown that 
inhibition and suppression of ADAM-10 via shRNA, siRNA and small molecule 
GI254023X, results in decreases in migration and invasion of oral squamous 
cell carcinoma, hepatocellular carcinoma (HepG2 cells), bladder cancer cells, 
and nasopharyngeal cancer cells (Jones, et al., 2013; Yuan, et al., 2013; Fu, 
et al., 2014; You, et al., 2015; Liu, et al., 2014; Mullooly, et al., 2016; 
Maretzky, et al., 2005).  These results, collectively suggest that ADAM-10 
may be an important contributing factor in cervical and oesophageal cancer 
progression. As tumour progression occurs, the cancer cells become more 
invasive and metastatic (Clark and Vignjevic, 2015; Yilmaz and Christofori, 
2009; Sethi, et al., 2011).  
 
In summary, our current study indicates that ADAM-10 has the potential to be 
an oesophageal and cervical cancer therapeutic target, as inhibition of its 
expression via GI254023X suppressed cancer cell migration, invasion, 
induced an increase in adhesion activity, suppressed pro-invasive changes in 
cell phenotype, and decreased vascular endothelial growth factor expression. 
Furthermore, our results have shown that for most of the parameters tested, 
SN-311 and SN-254 seem to have the same qualitative effect as GI254023X, 
strongly suggesting that these two novel agents may be causing these effects 
observed through inhibiting ADAM-10. However, we cannot exclude that 
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these results observed with SN-311 and SN-254 may be due to impacts on 
other molecular targets, or due to impacts on other ADAM receptors, such as 
ADAM-17. To address this, future possible specificity and binding studies 
should be conducted with possible targets. 		
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______________________________________________________________ 
Chapter 5: 
Conclusion 
 
 
In an earlier study conducted in our laboratory, we identified a number of 
genes differentially expressed genes in a microarray analysis performed in 
cervical tissue compared to normal tissue (van der Watt, 2009). One of the 
cDNAs shown to be highly expressed in the cancer samples, was one 
encoding the ADAM-10 protein (Ward, 2011). An additional expression 
profiling analysis was conducted in our laboratory in patient material isolated 
from cervical and oesophageal cancer and normal tissue samples. This 
expression pattern too indicated a significant up-regulation of ADAM-10 
expression in the cancer tissue material compared to that of the normal 
samples (Williams, 2013, MSc dissertation). This observation is consistent 
reports from other authors who performed similar expression profiling studies, 
demonstrating that ADAM-10 is overexpressed in a variety of tumours and 
contributes actively in cancer development and progression (Ma, et al., 2015; 
Mullooly, et al., 2016; Mullooly, et al., 2015; You, et al., 2015; Jones, et al., 
2013; Arribas, et al., 2006; Zhao, et al., 2014).  
 
The potential for ADAM-10 to serve as a therapeutic target in cervical and 
oesophageal cancer was investigated using the established GI254023X and 
two newly synthesized small molecules, namely SN-311 and SN-254. The 
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results in this study demonstrated that in at least two independent cancer cell 
lines, HeLa cervical, and WHCO5 oesophageal, a decrease of ADAM-10 
expression with GI254023X led to a decrease in markers of proliferation, a 
shift in the balance of phenotypic markers from mesenchymal to epithelial 
(based on the elevated levels of E-Cadherin and B-Catenin, and decrease in 
levels of Vimentin). The result obtained in GI254023X treatments was in 
accordance with literature, citing it as a small molecule able to decrease 
proliferation in a range of cancers, including breast, hepatocellular carcinoma 
and tongue squamous cell carcinoma (Duffy, et al., 2012; Fu, et al., 2014; 
Zhang, et al., 2014; Shao, et al., 2015).  
 
Prior work conducted in our laboratory had shown significant increases in cell 
adhesion in HeLa and WHCO5 when ADAM-10 was inhibited using shRNA 
ADAM-10 (Williams, 2013, unpublished data). Our data showed increases in 
cell adhesion after treatment with GI254023X, consistent with the elevated 
epithelial phenotypic markers detected. This generated result is in accordance 
with other studies in the literature (Maretzky, et al., 2005). Furthermore, our 
results showed significant reduction in migratory and invasive HeLa and 
WHCO5 cancer cells after treatment with GI254023X, suggesting a functional 
role that ADAM-10 has within cervical and oesophageal cancer cell migration 
and invasion properties. This finding correspond with other studies in different 
cell lines, which has shown that inhibition and suppression of ADAM-10 via 
shRNA, siRNA and GI254023X, had resulted in decreases in migration and 
invasion of oral squamous cell carcinoma, hepatocellular carcinoma (HepG2 
cells), bladder cancer cells, and nasopharyngeal cancer cells (Jones, et al., 
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2013; Yuan, et al., 2013; Fu, et al., 2014; You, et al., 2015; Liu, et al., 2014; 
Mullooly, et al., 2016; Maretzky, et al., 2005).   
 
Having detected a decrease in proliferative cancer cell activity after treatment 
with GI254023X, we investigated potential mechanisms involved. Our results 
had shown significant increases in caspase 3/7 activity levels in treatment 
with GI254023X, furthermore we determined that poly (ADP-Ribose) 
polymerase (PARP), a known caspase cleaved substrate (Bock and Chang, 
2016; Kotsopoulos, 2016) had increased in expression post treatment. This 
result suggests that apoptosis, is induced by GI254023X. Our findings with 
GI254023X treatment correspond with literature, whereby GI254023X was 
shown to not only block proliferation, but also induce apoptosis within acute T-
lymphoblastic leukaemia Jurkat cells (Mullooly, et al., 2016; Ma, et al., 2015).  
 
For all the markers examined in this study; inhibition of ADAM-10 with 
GI254023X in HeLa and WHCO5 cells is associated with the decrease in 
markers linked with tumorgenicity (proliferation, angiogenesis, migration and 
invasion), and in fact shown also to induce apoptosis. Of great significance, 
this study has shown that for most of the tumorgenicity parameters tested, the 
two novel compounds (SN-311 and SN-254) seem to have a similar 
qualitative effect as that of GI254023X seen in both HeLa and WHCO5 cells 
respectively. To assess whether the two novel small molecule compounds, 
would target ADAM-10, a human fractalkine CX3CL1 immunoassay was 
performed. ADAM-10 is described as a candidate for constitutive cleavage of 
CX3CL1, thus solubilizing this transmembrane bound protein via shedding 
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activity (Hundhausen, et al., 2003). Prior research has also shown that 
GI254023X is able to reduce significantly the cleavage of human fractalkine 
by preferentially blocking ADAM-10 receptor (Hundhausen, et al., 2003). Our 
results shown here in this functional ADAM-10 activity assay illustrated that 
both SN-311 and SN-254 were able to induce a decrease in cleaved soluble 
CX3CL1 expression levels, strongly suggesting that the two novel agents may 
well be causing the effects observed in the tumorgenicity parameters through 
inhibiting ADAM-10, as SN-311 and SN-254 were both able to inactivate 
CX3CL1 cleavage, a known ADAM-10 shedding function.   
 
However, we cannot conclusively say that SN-311 and SN-254 may be 
causing its effects by targeting ADAM-10 directly. Further binding and 
specificity studies are needed to be conducted to determine whether these 
compounds are indeed directly targeting ADAM-10. By performing these 
specificity assays we will know whether the results obtained are due solely by 
directly interacting with ADAM-10, or through impacting of other ADAMs, this 
as literature cites the ability of different ADAMs family members able to 
perform compensatory roles for each other. ADAM-10 is described as 
structurally and functionally related to ADAM-17, where both are shown to be 
leading proteases in trans-membrane protein ectodomains (Mullooly, et al., 
2016; Bzowska, et al., 2009). Furthermore, prior research has linked ADAM-
10 and ADAM-17 as able to compensate functionally in the absence of the 
other (Bzowska, et al., 2009).  
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5.1 Concluding statement 
In summary, our study has established that the two newly generated small 
molecules en route to synthesizing GI254023X, namely SN-311 and SN-254 
shares an EC50 concentration range in both oesophageal and cervical cancer 
cell lines; that SN-311 and SN-254 as able to target and inhibit the shedding 
of CX3CL1, an ADAM-10 functional activity. Furthermore, SN-311 and SN-254 
are able to suppress cellular proliferation, induce cell death by activating 
caspase 3/7 activity and increase cleavage of PARP, in a similar manner as 
GI254023X. This study also reports that ADAM-10 inhibition via GI254023X, 
inhibits cancer cell migration, invasion, and induces an increase in adhesion 
activity, suppresses pro-invasive changes in cell phenotype, and decreases 
vascular endothelial growth factor expression. Such findings were similarly 
detected in both novel compounds, SN-311 and SN-254. These results 
strongly suggest that ADAM-10 may play a critical role in maintaining the 
cancer phenotype in oesophageal cancer and cervical cancer, and that 
ADAM-10 may be a potential therapeutic target in these cancers. 
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Appendix A: 
Chemical Solutions Recipes 
 
 
 
A.1 Tissue culture solutions 
 
10X PBS (500ml)  
40 g NaCl  
1 g KCl  
5.75 g Na2HPO4.7H2O  
1 g KH2PO4  
Make up to 500ml with dH2O  
Autoclave this solution 
Dilute to 1x PBS when needed  
 
Heat Inactivated Foetal Calf Serum 
Heat FCS at 56°C for 30 minutes 
Store at -20°C until use 
 
Complete DMEM medium 
450 mL Dulbecco’s Modified Eagle’s Medium (DMEM) 
50 mL FCS 
5 mL Penicillin and streptomycin (P/S) 
 
Trypsinisation (Trypsin –EDTA) Solution (1000ml)  
0.5 g Trypsin  
8 g NaCl  
1.45 g Na2HPO4.2H2O  
0.2 g KCl  
0.2 g KH2HPO4  
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10 mM EDTA  
Make up to 1000 mL with 1X PBS  
 
Freezing Media (10ml)  
9 mL Complete DMEM Media 1ml 99% DMSO 
 
Hank’s balanced salt solution  
4.5 mM KCl  
0.3 mM Na2HPO4  
0.4 mM KH2PO4  
1.3 mM CaCl2  
0.5 mM MgCl2  
0.6 mM MgSO4  
137 mM NaCl  
5.6 mM D-glucose  
 
Hoechst stain (0.5 µg/ml)  
5 mg Hoechst No. 33258  
1000 mL Hank’s Balanced Salt Solution  
Store at 4°C in foil  
 
Fixing solution  
1:3 glacial acetic acid-methanol  
 
Mounting fluid  
22.2 mL 0.1 M citric acid  
27.8 mL 0.2 M Na2HPO4.2H2O  
50 mL glycerol  
pH 5.5 Store at 2-8°C  
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A.2 Western blot solutions 
 
RIPA buffer 
3 mL 5M NaCL (150mM) 
1 mL Triton X-100 (1%) 
1 g Na Deoxycholate (1%) 
1 mL 10% SDS (0.1%) 
1 mL 1M Tris pH. 7.5 (10mM) 
94 mL dH2O 
 
Complete RIPA 
450 µl RIPA  
50 µl 10X Protease Inhibitor (Sigma, USA) (104mM AEBSF. 80µM Aprotinin, 
4 mM Bestatin, 1.4mM E- 46, 2mM Leupeptin, 1.5mM Pepstatin)  
5 µl 0.1M Na3VO4  
Store at 4°C 
 
30% acrylamide solution  
30 g acrylamide  
0.8 g bisacrylamide  
0.1 g SDS  
Make up to 100 mL with dH2O  
Store at 4°C covered in foil  
 
Buffer 5X (15ml stock solution) 
SDS 10% (1,5gr) 
Glycerol 50% (7,5ml) 
beta-mercaptoethanol 25%  (3,75ml) 
Bromophenol blue 0,01% 
Tris-HCl pH 6,8 1,5M (3,13ml) 
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4 X Laemmli Loading Dye  
250 mM Tris‐Cl, pH 6.8  
6 % SDS  
0.005 % Bromophenol Blue  
40 % Glycerol  
10 % β‐mercaptoethanol  
 
10 X Running Buffer  
20 g Glycine  
31.6 g Tris  
50 mL 10 % SDS  
Up to 500 mL with dH2O  
 
10 X Transfer Buffer  
72 g Glycine  
19 g Tris  
Up to 500 ml with dH2O  
1X Transfer Buffer 
Dilute 100 mL 10X Transfer Buffer with 700 mL dH2O and add 200 mL 
methanol or Isopropanol. 
 
10X TBS (1000 mL)  
60.5 g Tris  
87.6 g NaCl pH7.5  
Make up to 1000 mL with dH2O 
 
1X TBST (1000 mL)  
100 mL 10X TBS  
900 mL dH2O  
1 mL Tween 20  
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A.3 Immunocytochemistry 
 
4% Paraformaldehyde (PFA)  
16 g PFA  
80 mL dH2O  
Cover with foil and stir for 1 hour not letting temperature exceed 60°C  
Add 10 M NaOH until clear  
Filter-sterilise  
Adjust to pH 7.0  
Store in 2.5 mL aliquots at -2o°C  
Add 7.5 mL 1X PBS to make 4% PFA  
 
 
50mM NH4Cl  
0.265 g NH4Cl  
100 mL 1X PBS  
 
Mowiol 4-88  
2 g Mowiol 4-88  
2 mL Glycerol  
4 mL dH2O  
Leave at RT O/N  
8 mL 0.2 M Tris (pH8.5)  
Incubate at 50°C for 1 hour  
Store in 2 mL aliquots at -20°C  
Add 2.5% Anti-Fading Agent (N-propyl gallate) day before use  
 
0.2% gelatin  
100 mg gelatin in 10 mL 1X PBS  
 
 
 
 
 
	 137	
 
A.4 Proliferation and drug treatment assays 
 
MTT Reagent (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide)  
5 mg/ml in PBS Weigh out 100 mg MTT in sterile 50 ml conical tube  
Add 20 ml sterile 1X PBS  
Vortex the mixture and incubate at 37°C for 15 minutes  
Filter sterilize the solution through a 0.2 µM filter Store in the dark at 4°C  
Use within 1 month  
 
Solubilisation Reagent  
10% Sodium Lauryl Sulphate (SLS) in 0.01 M HCl  
Filter sterilized Dissolve 25 g of SLS in 250 mL dH2O  
Add 76.6 µl concentrated HCl  
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Appendix B: 
Protein marker 
 
 
 
 
 
B.1: Protein molecular marker; Colour pre-stained Protein Standard, Broad 
range (11 – 245 kDa); 10 – 20% Tris-glycine SDS-Page. New England 
Biolabs (NEB), product number: #P7712. 
 
 
